

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (January 2001), Supplement 2 (January 2001), and Supplement 3 (April 2001) are preceded, respectively, by S1:, S2:, and S3:.

- | | | |
|---------------------------------|------------------------|-------------------------|
| Abbott, K.C., 366, 1304 | Azadian, B., 49 | Bonomini, M., 807 |
| Abu-Alfa, A.K., 294 | Azar, R., S2:81, 997 | Boots, J.M.M., 1170 |
| Acchiardo, S.R., 532 | | Borge, M.A., 1144 |
| Adams, P.L., 1152 | Baboolal, K., 400 | Bories, P., 4:E29 |
| Adhikari, M., 125 | Bailey, J.L., S2:112 | Borzak, S., 1191 |
| Adler, S., 1018 | Bailie, G.R., 766 | Bouvier, R., 4:E27 |
| Agodoa, L.Y., 366 | Bajo, M.A., 30 | Bower, J.D., 532 |
| Agodoa, L.Y.C., 276 | Bakr, M.A., 510 | Bowman, K., 1308 |
| Agro, A., S2:48 | Balestrieri, G., 490 | Braden, G., 5:E37 |
| Ahmad, S., 699 | Balogun, R.A., 1286 | Brady, R.C., 3:E22 |
| Ahmed, S., 4:E33, 1267 | Banfi, G., 490 | Brant, R., 64 |
| Akalın, E., 1:E8 | Barker, J., 945 | Brass, E.P., 1018 |
| Akçek, F., 588 | Barnas, U., 1247 | Breborowicz, A., 594 |
| Alamartine, E., 720 | Baron, C., 144 | Brem, A.S., 1 |
| Alappan, R., 294 | Başçi, A., 588 | Brenner, B.M., S2:48 |
| Alcántara, G., 43 | BaŞdemir, G., 1:E4 | Brezina, M., 308 |
| Alexander, B.D., 659 | Bass, E.B., 11 | Briscoe, D.M., 573 |
| Alexander, G.C., 321 | Bastani, B., 6:E45 | Bronsther, O., 612 |
| Alexander, J.W., 423 | Batiuk, T.D., 4:E33 | Brophy, P.D., 1044 |
| Alexander, S.R., 6:E44 | Batty, D.S., 1304 | Brown, A., S2:54 |
| Algur, N., 736 | Baylis, C., 900 | Brown, E.A., 49 |
| Ali, B., 1029 | Bayrak, R., 1:E4 | Bruijn, J.A., 653 |
| Allen, T.J., 890 | Beattie, J.N., 1191 | Brunner, F.P., 847 |
| Allon, M., 945 | Becker-Cohen, R., 736 | Brunskill, N.J., S2:17 |
| Alper, S.L., 632 | Beierwaltes, W.H., 900 | Buchmayer, H., 758 |
| Alpers, C.E., 518 | | Buisson, C., 144 |
| Al-Saloum, M., 300 | Belardi, P., 1253 | Bunchman, T.E., 1044 |
| Amato, A., 1018 | Bellini, C., 505 | Bushinsky, D.A., 1310 |
| Amato, D., 43 | Belson, A., 6:E44 | Butter, J., 5:E39 |
| Anbo, K., 4:E30 | Benedetto, B., 5:E37 | Butterly, D.W., 659 |
| Anderson, J., 1232 | Benigni, A., S2:21 | |
| Anderson, J.M., 970 | Bennett, W.M., 210 | Cagney, K.A., 11 |
| Anderson, R.J., 438 | Benson, D., 838 | Callen, L.J., 557 |
| Anderson, S., 601 | Berger, O., 3:E23 | Campbell, D., 1:E11 |
| Ando, M., 884 | Bernardini, J., 337 | Campbell, D.J., 890 |
| Ando, Y., 3:E21 | Berthezène, F., 720 | Canaud, B., S2:81, 997 |
| Ankermann, T., 624 | Berthou, F., 720 | Cano, N., S2:81, 997 |
| Aoyama, I., S2:7 | Bertini, I., 505 | Carey, H.B., 580 |
| Aparicio, M., S2:71, S2:81, 997 | Bertrand, Y., 4:E27 | Caridi, G., 1131 |
| Apfalter, P., 1:E10 | Bhathena, S.J., 1056 | Carlone, N.A., 1253 |
| Apsner, R., 758 | Bhimma, R., 125 | Carlsson, O., 1277 |
| Arduini, A., 807 | Bichet, D.G., 1290 | Carlton, D., 945 |
| Arkouche, W., S2:95 | Bieglmayer, C., 758 | Cartron, J-P., 518 |
| Armistead, N., 1232 | Biolo, G., S2:115 | Casalino, C., 1004 |
| Armstrong, D., 1:E11 | Birk, C.G., 790 | Casciani, C.U., 964 |
| Asai, A., 1216 | Bishop C.W., 532 | Cavallo, T., 423 |
| Asakawa, H., 1201 | Bispham, B.Z., 557 | Cely, C.M., 3:E24 |
| Asano, Y., 3:E21 | Bissler, J.J., 3:E22 | Chan, T.M., 94 |
| Asçi, G., 588 | Blagg, C.R., 987 | Chan, Y-L., 2:E17 |
| Atkins, R.C., 820 | Blahut, S.A., 348 | Chand, D.H., 3:E22 |
| Attaix, D., S2:108 | Blake, P.G., 22 | Chandrakantan, A., 1:E8 |
| Aukema, H.M., 73 | Bleyer, A.J., 1152 | Chandran, P.K.G., 4:E28 |
| Avram, M.M., S2:77 | Bohm, C., 484 | Chang, W., 1209 |
| | Bonnet, F., 720 | |

- Charytan, C., 300
 Chatha, R.K., 852
 Chattopadhyay, J., S2:77
 Chau, K.F., 544
 Chaudhury, P.R., 423
 Chauveau, P., S2:71, S2:81, 997
 Chen, C.-L., 418
 Chen, J.-H., 909
 Cheng, J.-T., 442
 Cheng, T.H., 287
 Cheng, Y.L., 544
 Chertow, G.M., 435, 743
 Chesney, R.W., 532
 Chi, H.S., 343
 Chilson, T.S., 1:E5
 Choi, K.S., 544
 Chorney, W., 580
 Chou, K.-J., 418
 Chow, K.-M., 2:E17
 Christiaans, M.H.C., 1170
 Chung, H.-M., 418
 Ciarcia, J., 1011
 Clarke, B.L., 1:E5
 Clemenger, M., 49
 Clorius, J.H., 1095
 Coburn, J.W., 532
 Cochat, P., 4:E27
 Cococcetta, N., 964
 Cohen, D.L., 1:E7
 Coimbra, T.M., 467
 Colin, Y., 518
 Collins, A.J., 938, 1177
 Combaret, L., S2:108
 Combe, C., S2:71, S2:81, 997
 Connolly, C.A., 125
 Constantiner, M., 638
 Contreras, G., 3:E24
 Cooper, C., 1039
 Cooper, M.E., 890
 Coovadia, H.M., 125
 Copley, J.B., 871
 Cosio, F.G., 797
 Covic, A.M.C., 638
 Cruz, D., 294
 Cuffini, A.M., 1253
 Cui, Y., 518
 Custer, J.R., 1044

 D'Agati, V.D., 388, 442, 1098
 D'Angelo, A., 233
 Danovitch, G.M., 866
 Daugirdas, J.T., 276
 Davenport, A., 457
 Davidson, R.C., 699
 de Jesús Ventura, M., 43
 Delarue, J., S2:103
 Delawari, E., S2:95
 Del Papa, N., 490
 Dentico, P., 1004
 Deprele, C., 720
 DeSoto, D.J., 790

 Desvaux, D., 144
 Dhamane, D., 144
 Dickmeyer, J., 938
 Diener-West, M., 921
 DiMarco, N.M., 73
 Doherty, T., 838
 Dohi, K., 499
 Doi, N., 411
 Don, B.R., 564
 Donaldson, L.A., 573, 1152
 Dor, A., 1223
 Douglass, L.L., 532
 Droz, D., 1324
 Drücke, T.B., S2:58
 Druml, W., S2:89
 Du, J., S2:112
 Duch, J.M., 149
 Duman, S., 588
 Dumlao, M., 612
 Durand, D., 4:E29
 Dusso, A., S2:54
 Dwight, C.A., 557

 Eddy, A.A., S2:25
 Edmunds, J.W., 73
 Eigner, M., 3:E23
 Eitner, F., 518
 Eknayan, G., 179
 El Agroudy, A.E., 510
 Elangovan, L., 532
 El-Diasty, T., 510
 Elisaf, M.S., 5:E41
 Ellis, E.N., 573
 El Sayed, K., 510
 Endoh, M., 380
 Enomoto, N., 499
 Epstein, F.H., 1113
 Epstein, M., 677
 Erturk, E., 612
 Esbrit, P., 30
 Eschbach, J.W., 179, 191
 Evan, A.P., 1267

 Fabien, N., 4:E27
 Fairman, R., 1:E7
 Faiyaz, R., 790
 Fan, J.-M., 820
 Fang, H.-C., 418
 Fatica, R.A., 1184
 Favaro, S., 233
 Fein, P., S2:77
 Feinstein, S., 736
 Feldkamp, J., 932
 Feldman, H.I., 134
 Finazzi-Agrò, A., 964
 Fink, J.C., 348
 Fink, N.E., 11
 Finkel, K.W., 1:E2, 2:E13, 3:E20,
 4:E26, 5:E35, 6:E43
 Finkelstein, F.O., 580, 1011
 Finkelstein, S.H., 1011

 First, M.R., 423
 Fishbane, S., 879
 Fisher, P.E., 1098
 Fitts, S.S., 987
 Fletes, R., 743
 Fliser, D., 79
 Floege, J., 400
 Flynn, J.T., 2:E15, 1044
 Föding, M., 758
 Fogo, A., 1:E1, 2:E12, 3:E19, 4:E25,
 871, 6:E42
 Fouque, D., S2:1, S2:81, S2:95, 997
 Franco, S.J., 777
 Frankenfield, D.L., 5:E36
 Frazão, J.M., 532
 Freeman, J., 5:E37
 Frei, G.L., 1098
 Fried, L., 337
 Friedman, G.S., 2:E18
 Frishberg, Y., 736
 Frohlich, E.D., 1092
 Frye, R.F., 766
 Fujita, T., 38
 Fukuhara, S., 987, 1216
 Futoo, Y., 1201

 Gabow, P.A., 852
 Gage, J., 743
 Gagnon, S., 300
 Galland, R., S2:95
 Gallay, B.J., 699
 Gambaro, G., 233
 Gang, X., 374
 Garg, M., 1191
 Garg, P.P., 921
 Garmany, R., 838
 Garovic, V.D., 1:E5
 Gehr, T., 1232
 Genega, E.M., 1:E7
 Ger, Y.-C., 728
 Gerbeau, C., 1:E11
 Ghali, W.A., 64
 Ghoneim, M.A., 510
 Giacchino, F., 1253
 Gil, F.Z., 467
 Gilbert, R.E., 890
 Gill, J., 484
 Gilli, P., 1004
 Girmdt, M., 954
 Gitnick, G., 308
 Gitomer, J.J., 1:E2, 2:E13, 3:E20,
 4:E26, 5:E35, 6:E43
 Goldberg, L., 49
 Golper, T.A., 179, 188
 Goodman, W.G., 197, 532
 Goodpaster, T., 518
 Gooley, T., 689
 Gordon, K.L., 601
 Goto, M., 1299
 Gotoh, M., 1:E6
 Grabe, D.W., 766

- Grabensee, B., 932
 Green, J., 987
 Greenberg, A., 659
 Grimbert, P., 144
 Grimm, E.M., 1:E2, 2:E13, 3:E20, 426, 5:E35
 Grisold, W., 3:E23
 Gröne, H., 400
 Gross, M., 202
 Grupp, C., 84
 Günal, A.I., 588
 Gupta, K.L., 119
 Gusmano, R., 505
 Gussak, H.M., 6:E45

 Hafeez, T., 300
 Hagen, W., 758
 Halperin, M.L., 1290
 Hamada, K., 728
 Hamburger, R.J., 1:E8
 Hamdy, A.F., 510
 Hammond, J.J., 890
 Hamrick, K., 945
 Hand, M., 573
 Hara, N., 728
 Harley, F.L., 573
 Hashimoto, K., 499
 Haslinger, B., 815
 Hataya, H., 4:E30
 Haufe, S., 1095
 Hauser, A.-C., 758
 Hayashi, T., 1140
 Hedgepeth, R.C., 104
 Heemann, U., 866
 Heer, M., 651
 Heilig, C., 1039
 Held, P.J., 276
 Hemmelgarn, B.R., 64
 Hemprich, U., 84
 Heninger, E., 1131
 Herman, A., 1029
 Hernández, D., 1260
 Herrera, J., 750
 Hetzel, G.R., 932
 Hiatt, W.R., 1018
 Higgins, J., 6:E44
 Hildebrandt, F., 1131
 Hill, G.S., 1324
 Hino, S., 138
 Hirata, D., 5:E38
 Hisano, S., 712
 Ho, S.K., 94
 Honda, M., 4:E30
 Honda, T., 1201
 Hong, C.D., 343
 Hood, A.F., 1267
 Horinaka, S., 1201
 Horio, T., 884
 Horita, Y., 884
 Hörl, W.H., 1:E3, 1:E10, 758, 859
 Hosoya, T., 987, 1216

 Houghton, D.C., 5:E40
 Hoy, W., 915
 Hsu, C.H., 195
 Hsu, S.-C., 4:E31
 Huang, J.-J., 4:E31, 1048
 Huang, T.-P., 427
 Huang, X.-R., 820
 Hudkins, K.L., 518
 Hughes, J., 601
 Hugo, C., 601
 Huizinga, T.W.J., 653
 Hulbert-Shearson, T.E., 276
 Humphreys, M.H., 564, 648
 Hung, S.-C., 427
 Hung, S.-H., 427
 Hurtado, M.E., 43

 Igarashi, T., 138
 Ignatescu, M., 758
 Ikeda, M., 138, 4:E30
 Ikeda, Y., 832
 Ikeguchi, H., 2:E14
 Imm, A., 1131
 Inatomi, J., 138
 Inenaga, T., 884
 Ing, T.S., 1144
 Ippolito, G., 1004
 Irwin, A., 981
 Isaacs, R.B., 160
 Ishibashi-Ueda, H., 884
 Ishimitsu, T., 1201
 Ito, S., 4:E30
 Iyengar, S.K., 638
 Izopet, J., 4:E29

 Janssen, U., 400
 Jarvis, W.R., 1232
 Jayapalan, S., 73
 Jedrey, C., 638
 Jefferson, J.A., 601
 Jerums, G., 890
 Jha, V., 119
 Jiménez, A., 1260
 Jinde, K., 380
 John, H., 84
 Johnson, A.M., 852
 Johnson, C.A., 5:E36
 Johnson, R.J., 601
 Jones, C., 276
 Joubran, N.I., 2:E16
 Joyama, S., 1:E6, 1299
 Jung, B., 22

 Kaider, A., 1247
 Kalantar-Zadeh, K., 564
 Kamar, N., 4:E29
 Kambham, N., 388, 442
 Kamel, K.S., 1290
 Kam-Tao Li, P., 2:E17, 329
 Kaneko, K., 1294
 Kang, D.-H., 601

 Kanwar, Y.S., 5:E39
 Kany, M., 4:E29
 Kaplan, A.A., 1286
 Kaplan, B., 1:E11
 Kara, M., 638
 Katano, K., 113
 Kaul, H., 954
 Kaur, P., 442
 Kaveh, K., 244
 Kawano, Y., 884
 Kaysen, G.A., S2:119
 Keane, J., 1:E8
 Keane, W.F., S2:1, S2:48
 Kelley, B.J., 532
 Kerjaschki, D., 601
 Kershaw, D.B., 1044
 Kew, M.C., 125
 Khosla, N., 1241
 Kiberd, B.A., 484
 Kim, S.B., 343
 Kim, Y.-G., 601
 Kimmel, P.L., 244
 Kimura, S., 38
 Kirk, A.D., 366
 Kirschstein, M., 624
 Kiyoshi, Y., 712
 Klauser, R., 1:E3
 Kliger, A.S., 580, 1011
 Knight, B., 1209
 Knowles, J.W., 1322
 Knudtson, M.L., 64
 Ko, C.W., 366
 Kobayashi, C., 1140
 Kobayashi, N., 1201
 Kobrin, S., 134, 1:E7
 Koga, M., 499
 Köhler, H., 954
 Kohli, H.S., 119
 Köller, E., 758
 Kon, S., 374
 Koni, I., 113
 Konner, P., 1:E10
 Konoshita, T., 113
 Kooistra, M.P., S2:99
 Kooman, J.P., 1170
 Kopple, J.D., S2:66
 Koshikawa, M., 1:E6, 1299
 Kostiner, D., 1069
 Kouli, F., 356
 Kovarik, J., 1:E3
 Kramvis, A., 125
 Kraus, E.S., 356
 Krysan, D.J., 2:E15
 Kuizon, B.D., 195
 Kumagai, T., 2:E14
 Kunis, C.L., 1098
 Kurbanov, A., 5:E37
 Kuriki, K., 3:E21
 Kurokawa, K., 380
 Kurosu, M., 3:E21
 Kurtzman, N.A., 636

- Kusano, E., 3:E21
 Kuwahara, T., 1:E6, 1299
 Kylo, D.M., 532

 Lacson, E., Jr., 267
 Lai, K.N., 94
 Lan, H.Y., 94, 820
 Lande, M.B., 5:E40
 Landsberg, D., 1162
 Lane, J.D., 1304
 Lang, P., 144
 Laville, M., S2:81, 997
 Law, M-C., 329
 Lazarus, J.M., 267, 743
 Leanos, B., 43
 Lederer, S.R., 815
 Lee, J.Y-Y., 1048
 Lee, S.K., 343
 Leehey, D.J., 1144
 Leithner, C., 3:E23
 Leitnaker, C.K., 954
 Lerma, E., 5:E39
 Leung, C-B., 329
 Leung-Sang Tang, N., 2:E17
 Leunissen, K.M.L., 1170
 Lerverve, X., S2:81, 997
 Levin, A., 484
 Levin, M.L., 5:E39
 Levin, N., 300
 Levin, N.W., 179
 Levine, B.S., 532
 Levine, D.Z., 1308
 Lew, N., 267
 Lewis, M., 1:E9
 Li, C.S., 544
 Liamis, G.L., 5:E41
 Light, P., 1232
 Light, P.D., 348
 Lilly, R.Z., 945
 Lin, S-H., 620
 Lin, T-K., 1048
 Lin, Y-F., 620
 Lipkowitz, G.S., 5:E37
 Litchfield, T., 938
 Little, J., 981
 Liu, H-L., 4:E31
 Liu-Jarin, X., 1098
 Lockridge, R., 777
 López-Barea, F., 30
 Lorenz, M., 1:E3
 Lorenzo, J.D., 550
 Lorenzo, V., 1260
 Lowrie, E.G., 267
 Lucas, S.R.R., 467
 Luft, F.C., 624, 629

 Mabuchi, H., 113
 Maccarrone, M., 964
 MacGregor, G.A., S2:34
 Mack, M., 518
 Mac-Moune Lai, F., 2:E17

 Madden, R., 5:E37
 Maecke, H.R., 847
 Maeda, K., 987
 Maeda, M., 374
 Maeda, N., 1322
 Mahnensmith, R., 294
 Maingourd, C., S2:103
 Malo, A.M., 1260
 Manca-di-Villahermosa, S., 964
 Mandl-Weber, S., 815
 Mandras, N., 1253
 Manley, H.J., 766
 Manley, J.A., 706
 Mansukhani, M.M., 388
 Marainen, J., 777
 Marengo, S.R., 104
 Markowitz, G.S., 388, 442, 1098
 Marshall, T., 981
 Martin, M., 1260
 Martin, P., 308
 Martin, S.S., 550
 Martinez, M.E., 30
 Martis, L., 594
 Marumo, F., 499
 Marx, M.A., 766
 Masaki, K., 728
 Massocco, D., 505
 Mate, A., 30
 Mathias, R.S., 1069
 Mathis, A.S., 2:E18
 Matsuo, S., 2:E14
 Matsuoka, H., 1201
 Mattern, W., 938
 Maung, H.M., 532
 Mayer, G., 56, 1247
 Mazess, R.B., 532
 Mazzalli, M., 601
 Mazzu, A., S2:48
 McAdams, A.J., 1120
 McClellan, W.M., 5:E36
 McCullough, P.A., 1191
 McIntosh, M., 1152
 McMahill, C.N., 938
 Meddendorf, D.F., 797
 Mehta, R.L., 22
 Meier-Kriesche, H-U., 1:E11
 Mele, A., 1004
 Meloni, C., 964
 Mendelssohn, D.C., 22
 Meneton, P., S2:39
 Mepani, B., 1029
 Merlino, C., 1253
 Meroni, P.L., 490
 Meunier, S., 4:E27
 Meyer, K.B., 11
 Meyer, R.J., 1044
 Mialou, V., 4:E27
 Mihatsch, M.J., 847
 Milionis, H.J., 5:E41
 Miller, E.R., 1232
 Minami, J., 1201

 Minota, S., 5:E38
 Miraglia, S.M., 467
 Miranda, G., 43
 Mitch, W.E., S2:1, S2:112
 Mittman, N., S2:77
 Miura, Y., 1216
 Miwa, M., 987
 Miyagi, K., 113
 Miyamori, I., 113
 Mizuno, M., 2:E14
 Moberly, J., 594
 Moe, S.M., 1267
 Mogensen, C.E., S2:2
 Mohr, P.E., 777
 Moll, S., 847
 Molony, D.A., 1:E2, 2:E13, 3:E20, 4:E26, 5:E35, 6:E43
 Mondry, A., 932
 Morgan, C., 1209
 Morita, Y., 2:E14
 Moroni, G., 490
 Morrell, C.H., 356
 Moss, A.H., 1081
 Moulin, P., 720
 Mu, W., 820
 Mueller, B.A., 766
 Mueller-Brand, J., 847
 Muhlbaier, L., 938
 Mullaney, S.R., 22
 Müller, D., 624
 Müller, G.A., 84
 Munda, R., 423
 Munzel, U., 84
 Murray, B.M., 1029
 Muthukumar, T., 119
 Mutoh, H., 113
 Myers, B.D., 438

 Nadasdy, T., 202
 Nagai, Y., 728
 Nagashima, T., 5:E38
 Nagata, S., 1216
 Nakahama, H., 884
 Nakai, S., 987
 Nakamoto, H., 1294
 Nakamura, K., 728
 Nakamura, S., 884
 Nakanishi, K., 728
 Nakao, A., 38
 Nakata, M., 1299
 Nakayama, K., 411
 Naruse, T., 374
 Nasr, E.M., 2:E16
 Natori, Y., 411
 Nava, M., 750
 Neumann, H.P.H., 852
 Neumann, P.J., 777
 Ng, Y-Y., 820
 Nickeleit, V., 847
 Nicoud, P., 4:E27
 Nielsen, J., 938

- Nikolic-Paterson, D.J., 820
 Nishikimi, T., 1201
 Nishina, M., 380
 Nissenson, A.R., 938, 1177
 Niwa, T., S2:7
 Nochy, D., 4:E27, 1324
 Noiri, E., 38
 Nojima, Y., 374
 Nomura, H., 113
 Norris, C.M., 64
 Norris, K.C., 532
 Nussbaumer, G., 1162

 Ogle, K., 594
 Ohnishi, M., 1216
 Ok, E., 1:E4
 Okada, H., 1294
 Okada, M., 138
 Okada, Y., 380
 Okazaki, H., 5:E38
 Okechukwu, C.N., 1:E11
 Okuda, N., 884
 Okusa, M.D., 4:E32, 838
 Oliver, J.D., III, 366
 Olson, J.M., 638
 O'Neill, K.D., 1267
 O'Neill, W.C., 706
 Onoe, T., 113
 Oo, K.K., S2:77
 Orazi, A., 388, 442
 Oreopoulos, D., 594
 Orlando, A.M., 1018
 Orzol, S.M., 276
 Oser, R., 945
 Otto, E., 1131
 Ou, Z.L., 411
 Ouseph, R., 316
 Owen, W.F., 267
 Owen, W.F., Jr., 179, 938, 5:E36
 Oya, A., 38
 Oyama, T.T., 601
 Özkahya, M., 588

 Packman, S., 1069
 Palella, F., 5:E39
 Pandeya, S., 484
 Paniagua, R., 43
 Panzeri, P., 490
 Papagiannopoulos, M., 758
 Parfrey, P.S., 154
 Park, J.S., 343
 Parrish, J., 1232
 Pastural, M., 144
 Paulson, W.D., 790
 Peddi, V.R., 423
 Perazella, M.A., 294
 Pereira, B.J.G., 938, 1177
 Perfumo, F., 505
 Peters, T.G., 366
 Peterson, R., 1011
 Petrosillo, N., 1004

 Pherson, K., 580
 Philipp, T., 866
 Philippe, N., 4:E27
 Phillips, A.O., 400
 Piaggio, G., 505
 Picken, M.M., 1144
 Pietschmann, P., 1247
 Piraino, B., 337
 Pogue, V.A., 442
 Polubinska, A., 594
 Pondarrè, C., 4:E27
 Ponticelli, C., 490
 Port, F.K., 276, 1184
 Powe, N.R., 11, 921
 Prial, M.M., 442
 Price, S.R., S2:112
 Puro, V., 1004

 Quaglini, S., 490
 Quan, H., 64

 Rabb, H., 1:E9
 Raffaele, J., 890
 Raggi, P., S2:62
 Ragni, P., 1004
 Rahman, S., 6:E45
 Rajczak, S., 1029
 Ram, S.J., 790
 Ramjee, G., 125
 Raschi, E., 490
 Ratner, L.E., 356
 Raveh, D., 736
 Rayner, H., 981
 Reale, M., 807
 Reddy, M., 348
 Regalado, M., 287
 Regele, H., 1:E3
 Rehak, P.H., 758
 Remuzzi, G., S2:21
 Remy, P., 144
 Resnick, M.I., 104
 Rettig, R.A., 862
 Revelo, M.P., 871
 Ribes, D., 4:E29
 Rickman, T., 838
 Rigby, R., 1209
 Riley, S., 400
 Rippe, B., 1277
 Ritz, E., 79
 Robertson, J.A., 532
 Rocco, M.V., 5:E36
 Rocklin, M.A., 557
 Rodriguez, H.J., 532
 Rodriguez, M., 1260
 Rodriguez, M.M., 550
 Rodriguez, R.A., 564
 Rodriguez-Iturbe, B., 750
 Romero, F., 750
 Romo, J.M.T., 550
 Rosas, S.E., 134
 Rosengren, B.-I., 1277

 Rosner, M.H., 4:E32
 Rostaing, L., 4:E29
 Roth, H., S2:81, 997
 Rothberg, P.G., 852
 Rubens, D., 612
 Rubin, H.R., 11
 Rubin, J.M., 1241
 Rufino, M., 1260
 Rutkowski, M., 532
 Ryan, M.J., 689

 Saab, S., 308, 1052
 Sabatini, S., 157
 Sabbagh, E., 638
 Saboorian, M.H., 73
 Sacks, S.H., 94
 Saddekni, S., 945
 Sadler, J.H., 11
 Sahadevan, M., 1286
 Saito, T., 411
 Saito, Y., 728
 Sakai, H., 380
 Sakemi, T., 832
 Sakhuja, V., 119
 Sakurai, T., 3:E21
 Saltissi, D., 1209
 Salusky, I.B., 197
 Sam, R., 1144
 Sanchez, E., 1260
 Sánchez, M.C., 30
 Sánchez-Cabezudo, M.J., 30
 Sandberg, K.R., 1191
 Sankarasubbaiyan, S., 1039
 Sasaki, S., 499
 Sasatomi, Y., 712
 Sassolas, A., 720
 Sawai, K., 1:E6, 1299
 Sawyers, E.S., 366
 Scalas, D., 1253
 Scandling, J.D., 438
 Schelling, J.R., 638
 Schifferli, J.A., 490
 Schlondorff, D., 518
 Schmidt, A., 56, 1247
 Schmidt, R.J., 900
 Schreiner, G.F., 601
 Schulte, K., 144
 Schuster, E., 56
 Schwab, S., 179, 190
 Scivittaro, V., 970
 Sedor, J.R., 638
 Segerer, S., 518
 Sehgal, A.R., 321, 638, 1223
 Seidl, G., 1247
 Selgas, R., 30
 Sen, S., 1:E4
 Senzaki, H., 1299
 Serra, G., 505
 Serraino, D., 1004
 Sester, M., 954
 Sester, U., 954

- Sevigny, J., 1286
 Shah, S., 5:E39
 Shah, S.V., S2:30
 Shalev, H., 736
 Shearer, G.C., S2:119
 Sheu, J.-N., 909
 Shichiri, M., 477
 Shiigai, T., 477
 Shimazu, K., 832
 Shimbo, T., 1216
 Shinzato, T., 987
 Shvil, Y., 736
 Sietsema, K.E., 1018
 Sigala, J.F., 532
 Silang, R., 287
 Singer, A., 84
 Singer, M.A., 164
 Singh, I., 797
 Sirolli, V., 807
 Sitter, T., 815
 Sivaraman, P., 1162
 Slatopolsky, E., S2:54
 Smith, S., 981
 Smith, S.R., 659
 Smoyer, W.E., 1044
 Sobh, M.A., 510
 Sobue, G., 2:E14
 Soman, S.S., 1191
 Sowinski, K.M., 766
 Specks, U., 1:E5
 Spencer, J., 915
 Spiegel, D.M., 557
 Sreedhara, R., S2:77
 Staffeld, C., 871
 Steadman, R., 400
 Stefenelli, T., 56
 Steinberg, E.P., 179, 1177
 Steinman, T.I., 938
 Stephani, U., 624
 Stiles, K.P., 1304
 Strang, J., 612
 Stuart, S., 4:E28
 Sud, K., 119
 Sue, Y.-M., 1048
 Suga, S.-i., 601
 Sugahara, S., 1294
 Sugawara, A., 1:E6, 1299
 Sunder-Plassmann, G., 758
 Sung, J.-M., 1048
 Suzuki, H., 1294
 Suzuki, T., 1201, 1294
 Szczech, L., 938
 Szelestei, T., 624
 Szeto, C.-C., 329
 Taccone-Gallucci, M., 964
 Taillandier, D., S2:108
 Takahashi, M., 1201
 Takai, I., 987
 Takano, A., 2:E14
 Takebayashi, S., 712
 Takeda, S., 3:E21
 Takeda, Y., 499
 Takemura, T., 138
 Takishita, S., 884
 Tamano, K., 1201
 Tanabe, R., 380
 Tanaka, A., 1:E6, 1299
 Tanaka, M., 728
 Tang, S., 94
 Tanji, N., 388
 Tarnag, D.-C., 427
 Taub, K.J., 64
 Teng, M., 267
 Testoni, C., 490
 Thomas, G.A., 5:E40
 Tincani, A., 490
 Ting, G., 777
 Toivola, B., 699
 Tokars, J.I., 1232
 Toma, H., 1140
 Tomaszewski, J.E., 1:E7
 Tonelli, M., 484
 Torres, A., 1260
 Townsend, R.R., 1:E7, 852
 Töz, H., 588
 Traeger, J., S2:95
 Trendelenburg, M., 490
 Tsai, A.C., 1223
 Tsai, M.-C., 4:E31
 Tsalamandris, C., 890
 Tsuji-Hayashi, Y., 987
 Tullio, V., 1253
 Uchida, S., 499
 Ueda, S., 1:E6, 1299
 Ueki, K., 374
 Uesugi, T., 832
 Uetake, S., 1201
 Uribarri, J., 1313
 Van der Sande, F.M., 1170
 Van Hooff, J.P., 1170
 Van Thiel, D.H., 1144
 Van Wyck, D.B., 300
 Velasquez, M.T., 1056
 Verburgh, C.A., 653
 Voroshilova, O., 797
 Vos, P.F., S2:99
 Vychytil, A., 1:E10
 Wagner, J., 879
 Walls, J., S2:13
 Wang, J.-S., 418
 Wang, M.-C., 4:E31, 1048
 Wang, Z., 915
 Warady, B.A., 573
 Ward, R.A., 316
 Warnock, D.G., S2:39
 Wasserstein, A., 134
 Watanabe, H., 2:E14
 Watschinger, B., 1:E10
 Weil, B., 144
 Weiss, M.F., 970
 Weitzel, W.F., 1241
 Welch, P.G., 366
 Wesson, D.E., 287
 West, C.D., 1120
 Westfall, A.O., 945
 Westhuyzen, J., 1209
 Whitwam, W., 1:E9
 Willers, R., 932
 Williams, J., 400
 Willnow, T.E., 624
 Wilmer, W.A., 797
 Winkelmayr, W.C., 3:E23
 Wish, J.B., 431, 5:E36
 Witte, D.P., 1120
 Wolfe, R.A., 276
 Wong, K.K., 544
 Wood, E.G., 573
 Wu, A.W., 11
 Wu, Q., 380
 Wuerth, D., 1011
 Xu, L., 699
 Yagisawa, T., 1140
 Yamakawa, T., 2:E14
 Yamamoto, H., 5:E38
 Yamano, S., 499
 Yamashita, Y., 499
 Yang, L., 104
 Yang, W.-C., 427
 Yang, W.S., 343
 Yee, H.F., Jr., 308
 Yee, J., 149, 1191
 Yee-Moon Wang, A., 2:E17
 Yetter, E.M., 1144
 Yiu, V., 573
 Yokoi, H., 1:E6, 1299
 Yorgin, P.D., 6:E44
 Yoshida, A., 1140
 Yoshida, F., 2:E14
 Yoshida, T., 1:E6, 1299
 Yoshioka, K., 138
 Young, B.A., 987
 Young, E.W., 1184
 Yu, A.W., 544
 Yuan, C.M., 1304
 Yuk-Hwa Wong, T., 329
 Yung, C.U., 544
 Zager, R.A., 689
 Zand, M.S., 202, 612
 Zenios, S.A., 435
 Zhou, X., 1092
 Zilch, O., S2:99
 Zivin, J.R., 689
 Zuccalà, A., 1319

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (January 2001), Supplement 2 (January 2001), and Supplement 3 (April 2001) are preceded, respectively, by S1:, S2:, AND S3:.

- Aboriginal children, low birth weight and reduced renal volume in, 915-920
- ACE gene polymorphism, polycystic kidney disease mortality and, 113-118
- ACEi. *See* Angiotensin-converting enzyme inhibitors
- ACTH. *See* Adrenocorticotrophic hormone, ectopic
- Acute renal failure (ARF)
 - cardiovascular disease and, 154-156
 - in gouty nephropathy with allograft failure, 871-875
 - hypocalcemia in critically ill patients and, 689-698
 - ischemic, 438-441
 - metabolic alterations, nutritional management and, S2: 89-94
 - with nephrotic syndrome and hepatitis C virus infection, 442-447
 - reversible, in paroxysmal nocturnal hemoglobinuria, 2:E17
 - risk, in nephrolithiasis, 233-243
 - shared decision-making in dialysis and, 1081-1091
- Acylcarnitine, effect on fatigue and exercise capacity in ESRD, 1018-1028
- Adenine phosphoribosyltransferase deficiency, allograft dysfunction and, 5:E37
- Adenocarcinoma, metastatic prostatic, Cushing's syndrome in, 838-846
- Adenovirus infection, post-transplant, 669
- Adequacy. *See also* Dose
 - hemodialysis
 - DOQI update, 181-188, S1:15-26
 - ESRD CPM project 2000 report, S3:21-25
 - flux of large molecular weight solutes and, S1:13
 - for pediatric patients, S1:10
 - peritoneal dialysis
 - CAPD outcome and, 329-336
 - clinical outcome goals for, S1:94-99
 - DOQI update, 188-190, S1:84-91
 - ESRD CPM project 2000 report, S3:39-40
- ADPKD. *See* Autosomal dominant polycystic kidney disease
- Adrenal adenoma diagnosis, aldosterone-renin ratio for, 699-705
- Adrenalectomy for primary aldosteronism, residual hypertension in, 884-889
- Adrenocorticotrophic hormone, ectopic
 - with hypokalemia, metabolic alkalosis and hypertension, 838-846
 - with nephrotic syndrome, 4:E28
- Adverse drug events
 - epoetin therapy, S1:217-219, 222
 - iron dextran-related, in hemodialysis, 743-749
- Adynamic bone disorder in elderly hemodialysis patients, protein intake effects, 1260-1266
- Age-related changes
 - allograft function and, 356-365
 - chronic renal failure in HMO and, 1177-1183
 - hemodialysis survival and, S2:81-88
 - incident peritoneal dialysis outcome prediction and, 337-342
 - nephropathy, impaired angiogenesis in, 601-611
 - total nitric oxide production and, 900-908
- AIDS
 - in child with lupus nephritis, 4:E27
 - malacoplakia and, 1324-1329
- Alanine aminotransferase, for hepatitis C screening, 308-315
- Albumin, serum
 - in hemodialysis
 - ESRD CPM project 2000 report, S3:35-37
 - prognostic importance of, S2:77-80
 - survival and, S2:81-88
 - low. *See* Hypoalbuminemia
 - in peritoneal dialysis
 - ESRD CPM project 2000 report, S3:44-46
 - incident outcome prediction and, 337-342
 - prognostic importance of, S2:77-80
 - warfarin effect on, 343-347
- Albumin excretion rate, in normotensive type 1 diabetics with microalbuminuria, perindopril vs. nifedipine for, 890-899
- Aldosterone, in progressive renal disease, 677-686
- Aldosterone-renin ratio, for primary aldosteronism screening, 699-705
- Aldosteronism, primary
 - residual hypertension after adrenalectomy, 884-889
 - screening without discontinuing antihypertensive therapy, 699-705
- Allograft
 - drug-induced acute interstitial nephritis or vasculitis in, 1:E4
 - dysfunction
 - adenine phosphoribosyltransferase deficiency and, 5:E37
 - from donor-transmitted atheroembolic renal disease, 423-426
 - failure
 - chronic, ACE inhibitors for, 866-870
 - early, in crescentic glomerulonephritis, 202-209
 - with foot pain, 871-875
 - rejection
 - chemokine and chemokine receptor expression in, 518-531
 - donor/recipient traits and, 356-365
 - of living related transplant, cyclosporine withdrawal and, 119-124

- recurrent focal segmental glomerulosclerosis and, 366-373
 - vascular, 1:E4
- survival
 - living kidney donors and, 366-373
 - underlying renal disease and, 1152-1161
 - traumatic fracture of, 4:E33
- Allometric scaling, of metabolic rate-glomerular filtration rate relationship, 164-178
- Alopecia with chronic renal failure, erythropoietin use and, 1:E9
- Aminoaciduria, selective, with renal glycosuria, 1039-1043
- Ammonia, metabolism of, 1070-1071
- Amphotericin B, administration and clearance during high-efficiency or high-efficiency/high-flux dialysis, 6:E45
- Anemia
 - epoetin therapy, S1:207-211
 - adverse response to, S1:217-219, 222
 - inadequate response to, S1:212-215, 222
 - in persistent nephrotic syndrome, 736-742
 - evaluation, S1:220
 - iron-deficiency
 - iron dextran for, 743-749, 859-861
 - iron sucrose for, 300-307
 - iron therapy for, S1:194-206, 221-222
 - persistent nephrotic syndrome and, 736-742
 - sodium ferric gluconate complex for, 879-883
 - management
 - DOQI updates, 191-194
 - for in-center hemodialysis, ESRD CPM project 2000 report, S3:28-35
 - for peritoneal dialysis, ESRD CPM project 2000 report, S3:41-44
 - red blood cell transfusions for, S1:216
 - target hemoglobin/hematocrit, S1:190-193, 220-221
 - work-up, S1:186-189
- Angiogenesis impairment, in aging kidney, 601-611
- Angioplasty
 - for hemodialysis patients, prediction of arteriovenous graft patency after, 945-953
 - preemptive, access blood flow after, 1029-1038
- Angiotensin-converting enzyme gene polymorphism, polycystic kidney disease mortality and, 113-118
- Angiotensin-converting enzyme inhibitors
 - antiproteinuric effect, late escape in nondiabetic renal disease, 477-483
 - for chronic renal failure, cardiac risk factor prevalence and, 484-489
 - for diabetic renal disease, S2:5
 - for hypertension, plasma aldosterone-renin ratio and, 699-705
 - for hypertensive renal disease, 677-686
 - for peritoneal dialysis patients with hypertension, vs. strict volume control, 588-593
 - in preventing chronic allograft failure, 866-870
 - with pulsed methylprednisolone and cyclosporine for proteinuria in familial focal segmental glomerulosclerosis, 6:E44
 - vs. calcium channel blocker for prevention of progression in diabetic nephropathy, 890-899
- Angiotensin II receptor blockers, renal-protective effects of, 677-686
- Anorexia, during continuous ambulatory peritoneal dialysis, S2:103-107
- Anterior pituitary insufficiency, and diabetes insipidus in Wegener's granulomatosis, 1:E5
- Antibiotic prophylaxis, for staphylococcal carriers, exit-site infection reduction and, 43-48
- Anti-Clq antibodies, lupus nephritis renal flare diagnosis, 490-498
- Antidepressant drugs, for depression in chronic peritoneal dialysis, 1011-1017
- Antidiuretic hormone, in partial central diabetes insipidus, 1290-1293
- Antihypertensive therapy. *See also* Angiotensin-converting enzyme inhibitors
 - for diabetic renal disease, S2:5
 - for end-stage renal disease, 677-686
 - primary aldosteronism screening and, 699-705
- Anti-inflammatory effects of dietary phytoestrogens, renal disease protection and, 1056-1068
- Antimicrobial resistance, vascular access infections at outpatient hemodialysis centers and, 1232-1250
- Antiviral therapy, post-transplant, 650-676
- APACHE II scores, correlation with hypocalcemia and death rate, 689-698
- ARF. *See* Acute renal failure
- Arginine overexcretion, in renal glycosuria, 1039-1043
- Argyria, in maintenance hemodialysis patients, 1048-1051
- Arrhythmia mortality, in renal failure patients after myocardial infarction, 1191-1200
- Arteriopathy, calcific uremic, in end-stage renal disease, 1098-1104
- Arteriosclerosis
 - imaging with electron beam tomography, S2:62-65
 - prediction of hypertension during pregnancy and, 728-735
 - residual hypertension after adrenalectomy for primary aldosteronism and, 884-889
- Arteriovenous fistulae
 - failure, oxidative stress and increased growth factor expression in, 970-980
 - monitoring for stenosis, S1:154-155
- Arteriovenous graft
 - blood flow assessment, after preemptive angioplasty, 1029-1038
 - diagnostic testing, S1:152-154
 - patency prediction, after radiologic intervention for hemodialysis, 945-953
- Ascites, nephrogenic, secondary hyperparathyroidism and, 2:E:16
- Association for the Advancement of Medical Instrumentation standards, for hemodialyzer reprocessing, S1:39
- AST-120, amelioration of renal overload of indoxyl sulfate and renal failure progression in diabetes, S2:7-12
- Atheroembolic renal disease, donor-transmitted, immediate allograft dysfunction from, 423-426
- Athletes, creatine supplementation for, 157-159
- Atrial natriuretic peptide, in hemodialysis patients, 1201-1208
- Autosomal dominant polycystic kidney disease
 - differentiation from von Hippel-Lindau disease, 852-858

- mortality, ACE polymorphism and, 113–118
screening in living kidney donor, T2-weighted MRI for, 612–619
- Bacteremia, from vascular access infections at outpatient hemodialysis centers and, 1232–1250
- Barter's syndrome, loop diuretic-sensitive Na-K-2Cl cotransporter and, S2:43–44
- Basiliximab, removal by plasmapheresis, 1:E11
- Beck Depression Inventory, identification of depression in chronic peritoneal dialysis, 1011–1017
- Beta-blocker, for thyrotoxic periodic paralysis, 620–623
- Bicarbonate hemodialysis, for extreme metabolic alkalosis, 4:E31
serum levels, home daily dialysis and, S2:99–102
- Bipolar disorder lithium intoxication, hemodialysis followed by continuous hemofiltration for, 1044–1047
- Birth weight, of Aboriginal children, 915–920
- Blacks
graft loss from recurrent FSGS and, 366–373
hemodialysis dosage, minimum delivered, S1:29
transplant access, reducing disparities in, 921–931
- Bleach, for dialyzer reprocessing, mortality risk and, 276–286
- Blood flow rate
of hemodialysis access
after preemptive angioplasty, 1029–1038
hemodynamic reproducibility and, 790–796
retrograde, prediction of access pathology and, 1241–1246
urea mass transfer area coefficient and, 316–320
- Blood pressure
ambulatory vs. office measurements, for chronic transplant nephropathy, 1170–1176
control
in diabetic renal disease, S2:4–5
renal apical Na transport systems in, S2:39–47
in diabetic renal disease, S2:3–5
elevation. *See* Hypertension
home daily dialysis and, S2:99–102
nitric oxide deficiency and, 900–908
salt intake and, S2:34–38
salt restriction and, 636–637
variation, influence graft blood flow measurements, 790–796
- Blood sampling procedures, for hemodialysis, S1:10–S11
- Blood transfusion
for anemia of chronic kidney disease, S1:216
hypocalcemia in critically ill patients and, 689–698
- Blood urea nitrogen
prediction of survival of renal failure patients after myocardial infarction, 1191–1200
sampling, DOQI clinical practice guidelines, S1:34–38
- Blood vessel prosthesis, blood flow measurements for thrombosis prediction, 790–796
- Body fluid volumes, salt intake and, 648–652
- Body mass determination, fat-free, edema-free, S1:82–83
- Body surface area estimation, S1:78–79
- Bone mineral density
QCT vs. DXA in chronic hemodialysis patients, 1247–1252
quantitative heel ultrasound for kidney transplant recipients, 932–937
- Bone turnover disease, osteoblastic cell growth vs. cultured cells in dialysis, 30–37
- Borah equation, pediatric modification, S1:83
- Bowman's capsule adhesion, idiopathic membranous nephropathy prognosis and, 380–387
- Brain injury, continuous renal replacement therapy, 457–466
- Brain natriuretic peptide, in chronic hemodialysis patients, 1201–1208
- Branchio-Oto-renal syndrome, nine families with, 505–509
- BUN. *See* Blood urea nitrogen
- CA 19-9, intraglomerular metastasis from pancreatic cancer and, 1299–1303
- Calciophylaxis
in end-stage renal disease, 1098–1104
hyperphosphatemia and increased osteopontin expression in vascular smooth muscle cells, 1267–1276
transcutaneous oxygen tension in, 797–806
- Calcium. *See also* Hypercalcemia; Hypercalciuria; Hypocalcemia
dysregulation in end-stage renal disease, 1310–1312
high dialysate, with midodrine and/or cool dialysate for intradialytic hypotension, 294–299
management in chronic renal failure, historical aspects of, 195–201
- Calcium-channel blocker, vs. ACE inhibitor for prevention of progression in diabetic nephropathy, 890–899
- Calcium oxalate crystallization, urinary protein inhibition of, 104–112
- Calcium stones
in medullary sponge kidney, contributory metabolic factors in, 1140–1143
renal failure risk and, 233–243
- CAPD. *See* Continuous ambulatory peritoneal dialysis
- Capillary rarefaction, angiogenesis impairment in aging kidney and, 601–611
- Carambola ingestion, oxalate nephropathy after, 418–422
- Cardiac output, glucocorticoid exposure and, 1–10
- Cardiopulmonary resuscitation preference rate, for Japanese dialysis patients, 1216–1222, 1308–1309
- Cardiovascular disease
calcifications, imaging with electron beam tomography, S2:62–65
with chronic renal failure, cardioprotective drugs in, 484–489
in end-stage renal disease, 154–156
incident peritoneal dialysis outcome prediction and, 337–342
- Carnitine therapy, effect on fatigue and exercise capacity in ESRD, 1018–1028
- Carnosine overexcretion, in renal glycosuria, 1039–1043
- Catalase, in chronic renal failure, effect of melatonin on, 750–757
- Catheters, cuffed tunneled catheters, survival comparison of, 557–563
- C3c glomerular deposits, in type 2 membranoproliferative glomerulonephritis, 1120–1130
- C4d and C4bp deposition, on glomerular capillary walls of preeclampsia, 1:E6

- Cefazolin
dialytic clearance, by high-efficiency and high-flux hemodialyzers, 766-776, 1111(erratum)
once-daily regimen for peritoneal dialysis in peritonitis, 49-55
- Central nervous system
dysfunction, in hyperammonemia, 1073-1075
glucocorticoid exposure and, 1-10
- Cerebral edema, continuous renal replacement therapy and, 457-466
- Cervastatin in Heart Outcomes in Renal Disease: Understanding Survival, protocol, S2:48-53
- Charlson Comorbidity Index, outcome prediction in incident peritoneal dialysis, 337-342
- Chemokine expression
in kidney transplantation rejection, 518-531
methylprednisolone for experimental crescentic glomerulonephritis and, 411-417
- Chemokine receptor expression, in kidney transplantation rejection, 518-531
- Children
Aboriginal, low birth weight and reduced renal volume in, 915-920
adequacy of hemodialysis for, S1:10
with anemia in persistent nephrotic syndrome, rHuEPO for, 736-742
on dialysis, mortality risk factors for, 573-579
hemodialysis dose
measurement of, S1:19-S23
minimum delivered, S1:29
with lithium intoxication, hemodialysis followed by continuous hemofiltration for, 1044-1047
with lupus nephritis and AIDS, 4:E27
nutrition assessment, modified Borah equation for, S1:83
with reversible posterior leukoencephalopathy and minimal-change nephrotic syndrome, 4:E30
traumatic fracture of renal allograft, 4:E33
- Chloride channel 5 gene mutations, in Dent's disease, 138-143, 227-228
- CHOICE Health Experience Questionnaire, 11-21
- Cholesterol emboli, 3:E19
- Cholesterol levels in dialysis, effect of lipid-lowering diet on, 1209-1215
- Chorea, thiamine deficiency-induced in hemodialysis, 427-430
- CHORUS (Cervastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol, S2:48-53
- Chronic renal failure (CRF)
with alopecia, possibly associated with erythropoietin use, 1:E9
anemia of. *See* Anemia
calcium and phosphorus management, historical aspects of, 195-196
cardiovascular disease and, 154-156
caused by yttrium 90-labeled DOTATOC- internal radiotherapy, 847-851
coronary risk factor prevalence, cardioprotective drugs and, 484-489
development, obesity and, 720-727
dialysis
mortality, erythropoietin and, 348-355
shared decision-making for, 1081-1091
in health maintenance organizations, 1177-1183
iron sucrose efficacy/safety for, 300-309
with metabolic alkalosis, bicarbonate hemodialysis for, 4:E31
nondiabetic, ACE inhibitor effect on proteinuria in, 477-483
nutrition guidelines, DOQI, S2:66-70
oxidative stress, effect of melatonin on, 750-757
progression. *See* Progressive renal disease
protein turnover in muscle, regulation of, S2:112-114
in secondary hyperparathyroidism. vitamin D derivatives for, S2:58-61
supplemented low-protein diet, nutritional consequences of, S2:71-76
transplant access, reducing racial disparities in, 921-931
CLCN5 gene mutations, in Japanese Dent's disease, 138-143
- Clinical Nephrology Meeting Abstracts, Tenth Annual, A1-A36
- Clinical performance measure, for profiling health care quality in dialysis, 267-275
- Clinical practice guidelines, for shared decision-making in dialysis, 1081-1091
- Coagulation factor VII, in CAPD, warfarin effect on, 343-347
- Co-amoxiclav, effect on polymorphonuclear granulocytes from chronic hemodialysis patients, 1253-1259
- Cold ischemia time, allograft function and, 356-365
- Comorbidity, incident peritoneal dialysis outcome prediction and, 337-342
- Complement C3 biosynthesis, stimulation in human proximal tubule epithelial cells, 94-103
- Compliance, of hemodialysis patients, 244-266
- Connective tissue disease, with pseudohypertension, 4:E32
- Conn's syndrome, residual hypertension after adrenalectomy, 884-889
- Continuous ambulatory peritoneal dialysis (CAPD)
hemostatic factors, warfarin effects on, 343-347
hypertension in, strict volume control for, 588-593
metabolic effects of dialysis fluids during, S2:103-107
outcome, peritoneal transport status and, 329-336
patient selection, prediction of, 981-986
peritonitis
once-daily cefazolin-based regimen for, 49-55
recurrent, rTPA for, 149-153
staphylococcal, 43-48
with uncommon organism and atypical clinical course, 1:E10
- Continuous quality improvement, limitations of standardized mortality ratio for, 267-275
- Continuous venovenous hemofiltration (CVVH)
with hemodialysis, for lithium intoxication in children, 1044-1047
for hyperammonemia in urea cycle disorders, 1069-1080
- Coordinated care, for dialysis patients, 938-944
- Coronary angiography, for NDDRI patients, poor long-term survival and, 64-72
- Coronary artery disease, brain natriuretic peptide in hemodialysis patients and, 1201-1208

- Coronary care unit, survival of renal failure patients after MI and, 1191-1200
- Cortex echogenicity, quantification of, 706-711
- Cost, of daily hemodialysis, 777-789
- Counseling, in selection of dialysis modality, 981-986
- CPR preference rate, for Japanese dialysis patients, 1216-1222
- Creatine supplementation, by athletes, 157-159
- Creatinine, serum
- renal dysfunction in elderly and, 79-83
 - serum
 - chronic renal failure in health maintenance organization and, 1177-1183
 - idiopathic membranous nephropathy prognosis and, 380-387
 - prediction of survival of renal failure patients after myocardial infarction, 1191-1200
 - prognostic importance in HD and PD, S2:77-80
- Creatinine clearance
- idiopathic membranous nephropathy prognosis and, 380-387
 - of kidney transplant recipient, allograft function and, 356-365
 - prediction of survival of renal failure patients after myocardial infarction, 1191-1200
- Creatinine dialysate-to-plasma ratio, CAPD outcome and, 329-336
- Crescent formation, idiopathic membranous nephropathy prognosis and, 380-387
- CRF. *See* Chronic renal failure
- Critical illness, hypocalcemia in, 689-698
- Cubulin, albumin binding, S2:18
- Cushing's syndrome
- in metastatic prostatic adenocarcinoma, 838-846
 - with nephrotic syndrome, 4:E28
- CVVH. *See* Continuous venovenous hemofiltration
- Cyclic guanosine monophosphate, effects of aging and sodium intake on, 900-908
- Cyclosporine
- hyperuricemia-associated with, 871-875
 - with ketoconazole for kidney transplant recipients, long-term follow-up of, 510-517
 - kinetics during membrane-based apheresis, effect of plasma exchange on, 1286-1289
 - nephrologist-industry relationship and, 210-221
 - with pulsed methylprednisolone and ACE inhibitor for proteinuria in familial focal segmental glomerulosclerosis, 6:E44
 - withdrawal, impact on living related renal transplants, 119-124
- Cystatin C, renal dysfunction in elderly and, 79-83
- Cystine lithiasis, renal insufficiency and, 234
- Cystinuria, renal failure risk and, 234
- Cytokines
- in hypocalcemia of critical illness, 689-698
 - production, lipopolysaccharide-induced in monocytes during hemodialysis, 954-963
 - renal disease progression and, S2:21-24
- Cytomegalovirus, post-transplant, 664-666
- DASH diet, salt restriction and, 636-637
- D-dimer in CAPD, warfarin effect on, 343-347
- Dense deposit disease. *See* Membranoproliferative glomerulonephritis, type 2
- Densitometry, in quantification of renal cortical echogenicity, 706-711
- Dent's disease, chloride channel 5 gene mutations in, 138-143, 227-228
- Depression, identification and treatment in chronic peritoneal dialysis, 1011-1017
- Diabetes insipidus
- and anterior pituitary insufficiency in Wegener's granulomatosis, 1:E5
 - partial central, pathophysiology and treatment for, 1290-1293
- Diabetic renal disease
- chronic renal failure in health maintenance organization and, 1177-1183
 - complications, control of, S2:2-6
 - gene identification, family-based strategy for, 638-647
 - hemodialysis dosage, minimum delivered, S1:29
 - hemodialysis survival and, S2:81-88
 - incident peritoneal dialysis outcome prediction and, 337-342
 - non-insulin-dependent, age-dependent renal structural changes and, 400-410
 - progression
 - AST-120 amelioration of renal overload of indoxyl sulfate in, S2:7-12
 - prevention, perindopril vs. nifedipine for, 890-899
 - protein turnover in muscle and, S2:112-114
 - uncontrolled, with hyperosmolar syndrome, 5:E41
- Dialysate
- collection, S1:80
 - cool, with high dialysate calcium and midodrine for intradialytic hypotension, 294-299
 - flow rate, mass transfer area coefficient and, 316-320
- Dialysis. *See also specific dialysis modality*
- modality selection
 - nephrologists and, 22-29
 - prediction of patient's choice, 981-986
 - mortality, pre-ESRD erythropoietin and, 348-355
 - nephrologist-industry relationship and, 210-221
 - patients
 - cultured osteoblastic cells, vs. osteoblastic cell growth in bone turnover disease, 30-37
 - disease-state management for, 938-944
 - health-related quality of life in, 987-996
 - pediatric, mortality risk factors for, 573-579
 - withholding/withdrawal, shared decision-making in, 1081-1091
- Dialysis Outcomes Quality Initiative (DOQI)
- update, 179-180, S1:9
 - anemia of chronic kidney disease, S1:183-235
 - dissenting view on nutrition in long-term PD, 1313-1319
 - hemodialysis adequacy, S1:7-61
 - peritoneal dialysis adequacy, S1:66-133
 - vascular access, S1:138-179
- Work Group members
- anemia, S1:236-238

- hemodialysis, S1:62-64
 - peritoneal dialysis, S1:134-136
 - vascular access, S1:180-181
- Dialyzer clearance, effects of blood and dialysate flow rates, 316-320
- Dialyzer reuse
 - DOQI update, S1:11
 - mortality risk and, 276-286
 - nephrologist-industry relationship and, 210-221
- Diet
 - compliance, of hemodialysis patients, 246-248
 - lipid-lowering, efficacy for dyslipidemia in end-stage renal disease, 1209-1215
 - supplemented low-protein, safety of, S2:71-76
- Digoxin, with itraconazole for kidney transplant recipients, 2:E18
- Disease Outcomes Quality Initiative (DOQI), 179-180
 - anemia treatment, in chronic kidney disease, 191-194
 - hemodialysis adequacy updates, 181-188
 - peritoneal dialysis adequacy updates, 188-190
 - vascular access updates, 188-190
- Disease-state management, for end-stage renal disease, 938-944
- Doppler ultrasound, of retrograde hemodialysis access flow, as predictor of access pathology, 1241-1246
- DOQI. *See* Dialysis Outcomes Quality Initiative
- Dose
 - hemodialysis, S1:14
 - delivered, measurement of, S1:15-S26
 - DOQI update, S1:10, 27-33
 - errors in prescribing, S1:17-S18
 - frequency of measurement, S1:32-33
 - inadequate, morbidity and cost implications of, 1223-1231
 - measurement of, S1:19-S23
 - minimum delivered, S1:27-30
 - prescribed, S1:30-32
 - troubleshooting, S1:42-44
 - peritoneal dialysis, S1:84-91
 - methods for measurement of, S1:72-77
 - reproducibility of measurement, S1:78, 118-120
 - timing of measurement, S1:79-80
- DOTATOC internal radiotherapy, causing thrombotic microangiopathy, 847-851
- Doxercalciferol, intravenous vs. oral for secondary hyperparathyroidism, 532-543
- Drug toxicity, hemodialysis with continuous hemofiltration for, 1044-1047
- Dual-energy x-ray absorptiometry
 - vs. QCT in chronic hemodialysis patients, 1247-1252
 - vs. quantitative heel ultrasound in transplant recipients, 932-937
- Duffy antigen receptor expression, in renal transplant rejection, 518-531
- Dyslipidemia
 - in end-stage renal disease, efficacy of lipid-lowering diet for, 1209-1215
 - hypertension and, 1319-1323
- E-cadherin loss, interleukin-1-induced TEMT and, 820-831
- Echocardiography, for CAD screening of renal replacement therapy patients, 56-63
- Echogenicity of cortex, quantification of, 706-711
- Elderly
 - hemodialysis patients
 - effect of protein intake on phosphorus and PTH levels, 1260-1266
 - factors influencing survival in, 997-1003
 - renal dysfunction, serum cystatin D concentration and, 79-83
- Encephalopathy, hyperammonemic, 1069-1080
- End-of-life decisions, preference rate for CPR in Japanese dialysis patients and, 1308-1309
- Endothelin-1
 - increased expression in hemodialysis access failure, 970-980
 - renal disease progression and, S2:21-24
- Endourological techniques, renal function effects, 238-240
- End-stage renal disease (ESRD)
 - antihypertensive therapy for, 677-686
 - calciphylaxis, transcutaneous oxygen tension in, 797-806
 - calcium and phosphorus management in, historical aspects of, 195-196
 - CHORUS trial in, S2:48-53
 - depression with peritoneal dialysis, antidepressants for, 1011-1017
 - in diabetic nephropathy, family-based strategy for gene identification in, 638-647
 - disease-state management for, 938-944
 - DOQI update and, S1:9
 - with dyslipidemia, efficacy of lipid-lowering diet for, 1209-1215
 - dysregulation of calcium, phosphorus and PTH and vitamin D axis, 1310-1312
 - exercise capacity, carnitine therapy for, 1018-1028
 - in extended care facility, continuous peritoneal dialysis for, 580-587
 - fatigue, carnitine therapy for, 1018-1028
 - health-related quality-of-life measures, 11-21
 - hypoalbuminemia, prokinetic agents for, 287-293
 - iron dextran-related adverse drug events and, 743-749
 - kidney transplantation process, failure to complete, 321-328
 - with liver disease, transjugular renal biopsy for, 1144-1151, 1304-1307
 - nephrolithiasis and, 235, 237
 - nephrologist-industry relationship and, 210-221
 - outcome prediction on incident peritoneal dialysis, 337-342
 - oxidative stress, melatonin effect on, 750-757
 - in polycystic kidney disease, ACE gene polymorphisms and, 113-118
 - from renovascular disease, incidence trends and mortality in, 1184-1190
 - subcutaneous EPO, lower dose and equivalent hematocrit in, 5:E36
 - transplant access, reducing racial disparities in, 921-931
 - with uremic myopathy, 1098-1104

- vascular access infections at outpatient hemodialysis centers and, 1232-1250
- End-Stage Renal Disease Core Indicators Project, results from, 5:E36
- Energy intake of dialysis patients, effect of lipid-lowering diet on, 1209-1215
- Epithelial cell transdifferentiation, interleukin-1 induced, 820-831
- Epithelial sodium ion channel, amiloride-sensitive, blood pressure control and, S2:40-42
- EPO. *See* Erythropoietin
- Epoetin therapy, DOQI update, 191-194, S1:207-211
- adverse effects, S1:217-219, 222
- inadequate response, S1:212-215, 222
- Epstein-Barr virus infection, post-transplant, 659-676
- Erectile dysfunction in dialysis patients, sildenafil for, 134-137
- Erythrocyte phagocytosis susceptibility in uremia, PS-recognition mechanism and, 807-814
- Erythropoiesis
- assessment during hemodialysis, 550-556
- home daily dialysis and, S2:99-102
- Erythropoietin (EPO)
- chronic renal failure with alopecia and, 1:E9
- deficiency, S1:188-189
- persistent nephrotic syndrome and, 736-742
- pre-ESRD, impact on dialysis mortality, 348-355
- recombinant human
- for anemia in persistent nephrotic syndrome, 736-742
- during hemodialysis, erythropoiesis assessment for, 550-556
- oxidative stress, melatonin prevention of, 750-757
- subcutaneous, effect on dose and hematocrit in adult hemodialysis patients, 5:E36
- Escherichia coli*, heat-killed, induction of PAI-1 in mesothelial cells, 815-819
- ESRD. *See* End-stage renal disease
- ESRD Clinical Performance Measures Project Annual Report for 2000
- appendices, S3:47-69
- background and project methods, S3:12-19
- executive summary, S3:8-12
- in-center hemodialysis patients, S3:20-37
- peritoneal dialysis patients, S3:38-46
- Estrogens, plant-based, glomerular injury in hypercholesterolemia and, 832-837
- Ethical issues, nephrologist-industry relationship and, 210-221
- Exercise
- capacity, in ESRD, carnitine therapy for, 1018-1028
- traumatic fracture of renal allograft, 4:E33
- Exercise electrocardiography, for CAD screening of renal replacement therapy patients, 56-63
- Exit-site infection, mupirocin prophylaxis for staphylococcal carriers and, 43-48
- Expanded polytetrafluoroethylene graft failure, oxidative stress and increased growth factor expression in, 970-980
- Extended care facility, continuous peritoneal dialysis in, 580-587
- Extracorporeal shockwave lithotripsy, renal function effects, 238-240
- Fabry disease, 4:E25
- Familial focal segmental glomerulosclerosis, proteinuria, pulsed methylprednisolone, cyclosporine and ACE inhibitor for, 6:E44
- Fanconi' syndrome, holoprosencephaly with low molecular weight proteinuria and, 624-628
- Fatigue in ESRD, carnitine therapy for, 1018-1028
- Ferric gluconate complex, for dialysis-associated iron deficiency anemia, 879-883
- Ferritin, serum
- in dialysis-associated anemia, iron sucrose therapy for, 300-307
- as marker for morbidity and mortality in hemodialysis, 564-572
- Ferrokinetic measurements, for erythropoiesis assessment during hemodialysis, 550-556
- Fibrinogenic factors, stimulation of synthesis of extracellular matrix proteins, S2:25-29
- Fibrinolysis, during bacterial peritonitis, PAI-1 expression in mesothelial cells and, 815-819
- Filter-cake hypothesis, testing of, 1277-1285
- Fistula, retrograde flow, as predictor of hemodialysis access pathology, 1241-1246
- Flaxseed, role in renal disease protection, 1056-1068
- Flow cytometry, selective sequestration of cytokine-producing monocytes during hemodialysis, 954-963
- Fluid intake, of hemodialysis patients, interdialytic weight gain and, 247-262
- Focal segmental glomerulosclerosis, recurrent, allograft rejection and, 366-373
- Folic acid, for hyperhomocysteinemia in hemodialysis, 758-765
- Food restriction, intrauterine, glomerulosclerosis and, 467-476
- Fusobacterium necrophorum* bacteremia, hemolytic uremic syndrome in, 3:E22
- Gastric emptying delay in hypoalbuminemia of chronic dialysis patients, prokinetic agents for, 287-293
- Gastrointestinal obstruction metabolic alkalosis, bicarbonate hemodialysis for, 4:E31
- Gemella morbillorum*-induced shunt nephritis, proteinase 3 antineutrophil cytoplasmic autoantibody in, 5:E38
- Gender
- allograft function and, 356-365
- chronic renal failure in health maintenance organization and, 1177-1183
- Gene mutations, in Japanese Dent's disease, 138-143, 227-228
- Generic medications, nephrologist-industry relationship and, 210-221
- Genetic studies
- family-based strategy for diabetic nephropathy identification, 638-647

- holoprosencephaly with low molecular weight proteinuria, 624-628
- GFR. *See* Glomerular filtration rate
- Gitelman's syndrome, Na-Cl cotransporter gene mutations, S2:42-43
- Glomerular arterioles, in hypertension, 1092-1097
- Glomerular basement membrane thickening, in prolonged hyperglycemia, 400-410
- Glomerular capillary lumina, intraglomerular metastasis from pancreatic cancer and, 1299-1303
- Glomerular capillary walls, C4d and C4bp deposition in pre-eclampsia, 1:E6
- Glomerular deposits, in type 2 membranoproliferative glomerulonephritis, 1120-1130
- Glomerular disease
 - primary, urinary osteopontin in, 374-379
 - proteinuria, oxidants and, S2:30-33
- Glomerular filtration, of albumin, S2:17
- Glomerular filtration rate (GFR)
 - in elderly, renal dysfunction and, 79-83
 - glucocorticoid exposure and, 1-10
 - metabolic rate and, 164-178
 - perindopril vs. nifedipine for normotensive type 1 diabetics with microalbuminuria, 890-899
- Glomerular hypertrophy, intrauterine food restriction and, 467-476
- Glomerulocystic kidney, with subacute necrotizing-encephalomyelopathy, 2:E14
- Glomerulonephritis
 - childhood IgA, macrophage subclasses in, 712-719
 - crescentic
 - early renal allograft loss in, 202-209
 - pulse methylprednisolone efficacy in, 411-417
 - in hypocomplementemic urticarial vasculitis syndrome, 144-148
 - membranoproliferative. *See* Membranoproliferative glomerulonephritis
 - poststreptococcal, macrophage subclasses in, 712-719
 - posttransplantation survival and, 1152-1161
 - rapidly progressive, with hypopharyngeal carcinoma, 1:E3
- Glomerulopathy, collapsing, early allograft loss in crescentic glomerulonephritis and, 202-209
- Glomerulosclerosis
 - idiopathic membranous nephropathy prognosis and, 380-387
 - intrauterine food restriction and, 467-476
 - residual hypertension after adrenalectomy for primary aldosteronism and, 884-889
- Glucocorticoids
 - control of protein breakdown, S2:108-111
 - hypertension associated with, 1-10
 - induced metabolic alkalosis, with hypokalemia and hypertension, 838-846
 - proteolytic capacity of muscle and, S2:112-114
 - pulse therapy, for experimental crescentic glomerulonephritis, 411-417
- Glucose transporter, in renal glycosuria with selective aminoaciduria, 1039-1043
- Glutathione, in chronic renal failure, effect of melatonin on, 750-757
- Glycerophosphorylserine, inhibition of phagocytosis of uremic erythrocytes, 807-814
- Glycosuria, with overexcretion of arginine, carnosine and taurine, 1039-1043
- Gouty nephropathy, with allograft failure, 871-875
- Graft. *See* Vascular access
- Granulocyte colony-stimulating factor, intraglomerular metastasis from pancreatic cancer and, 1299-1303
- Growth factors, renal disease progression and, S2:21-24
- Growth hormone excretion, in Japanese Dent's disease, 138-143
- Hamilton Depression Scale, identification of depression in chronic peritoneal dialysis, 1011-1017
- Head injury, partial central diabetes insipidus from, 1290-1293
- Health care costs, cyclosporine withdrawal and, 1119-1124
- Health Care Financing Administration, daily hemodialysis and, 862-865
- Health maintenance organization, chronic renal failure in, 1177-1183
- Health services
 - accessibility
 - failure to complete transplantation process and, 321-328
 - reducing racial disparities in transplant access, 921-931
 - planning, prediction of patient's choice of dialysis modality, 981-986
- Hematocrit
 - subcutaneous EPO for ESRD hemodialysis patients and, 5:E36
 - target, for treating anemia of chronic kidney disease, S1:190-193, 220-221
 - urea mass transfer area coefficient and, 316-320
- Hemodialysis (HD)
 - access. *See* Vascular access
 - adequacy. *See* Adequacy, hemodialysis
 - anemia-associated with. *See* Anemia, iron-deficiency
 - applicability, S1:14
 - arteriovenous graft patency prediction, after radiologic intervention, 945-953
 - blood sampling procedures, S1:10-11
 - bone mineral density evaluation methods, comparison of, 1247-1252
 - brain natriuretic peptide in, 1201-1208
 - calciphylaxis, transcutaneous oxygen tension in, 797-806
 - compliance, 244-266
 - coronary artery disease screening, noninvasive, 56-63
 - cuffed tunneled catheters, survival comparison of, 557-563
 - daily
 - clinical outcome, S2:99-102
 - HFCA implications of, 862-865
 - impact on costs and quality of life, 777-789
 - short, nutritional status and, S2:95-98
 - discontinuation preferences for Japanese patients, 1216-1222
 - dose. *See* Dose, hemodialysis
 - duration of treatment, S1:22
 - erythropoiesis assessment during, 550-556
 - evidence-based vs. opinion-based, S1:14

- followed by continuous hemofiltration for lithium intoxication in children, 1044-1047
frequency, nutritional status and, S2:95-98
hepatitis C virus. *See* Hepatitis C virus
for hyperammonemia in urea cycle disorders, 1069-1080
hyperhomocysteinemia in, folic vs. folic acid for, 758-765
hypotension, thoracoscopic pericardiectomy for, 1294-1298
initiation, appropriate timing for, S1:13-S14
lipid profile, effect of lipid-lowering diet on, 1209-1215
5-lipoxygenase-mediated oxidative stress in monocytes, vitamin E suppression of, 964-969
maintenance
 effect of protein intake of elderly on phosphorus and PTH levels, 1260-1266
 generalized argyria in, 1048-1051
 modified urea reduction ratio for, 544-549
 monocyte sequestration, subtype-specific, 954-963
 nutrition, S1:14
 patient
 comfort, adherence, DOQI guidelines, S1:11-S13
 elderly, factors influencing survival in, 997-1003
 failure to complete transplantation process, 321-328
 quality-of-life, S1:14
 rehabilitation, S1:14
 polymorphonuclear granulocytes, co-amoxiclav effect on, 1253-1259
 prescription, maximizing patient adherence, S1:45-47
 selection
 nephrologists and, 22-29
 prediction of, 981-986
 survival
 nutritional factors, dialysis adequacy and, S2:81-88
 predialysis supplemented low-protein diet and, S2:75
 prognostic importance of nutritional markers, S2:77-80
 thiamine deficiency, induction of chorea in, 427-430
 urea mass transfer area coefficient, dialysate flow rate and, 316-320
Hemodialysis center understaffing, hepatitis C virus transmission during hemodialysis and, 1004-1010
Hemodialysis membranes
 biocompatibility, S1:13
 high-flux synthetic reuse of, mortality risk and, 276-286
Hemodialyzers
 high-efficiency and high-flux, cefazolin dialytic clearance by, 766-776, 1111(erratum)
 reprocessing/reuse, DOQI guidelines, S1:39-41
Hemodynamics, home daily dialysis and, S2:99-102
Hemoglobin
 below-target levels, iron sucrose therapy for, 300-307
 target, for treating anemia of chronic kidney disease, S1:190-193, 220-221
Hemolytic uremic syndrome
 in *Fusobacterium necrophorum* bacteremia, 3:E22
 Streptococcus pneumoniae-associated, renal transplantation after, 2:E15
Hepatitis B virus carrier state, of contacts with membranous nephropathy, 125-133
Hepatitis C virus
 infection
 with nephrotic syndrome and renal failure, 442-447
 with reversible posterior leukoencephalopathy syndrome, 4:E29
 screening, alanine aminotransferase for, 308-315
 transmission, risk factors for, 1004-1010
Hereditary disease, caused by de novo ENaC mutations, 499-504
Herpes simplex virus infections, post-transplant, 659-676
High-efficiency or high-efficiency/high-flux dialysis, amphotericin B administration and clearance during, 6:E45
History of medicine, John P. Peters and, 1113-1119
HIV-associated nephropathy, occurring before HIV antibody seroconversion, 5:E39
HMO (health maintenance organization), chronic renal failure in, 1177-1183
Holoprosencephaly, with low molecular weight proteinuria, 624-628
Home daily dialysis, clinical outcome, S2:99-102
Homocysteine, plasma level reduction by folic vs. folic acid, 758-765
Hospitalization
 for inadequate hemodialysis, morbidity and cost implications of, 1223-1231
 for renal disease-state management, 938-944
HUS. *See* Hemolytic uremic syndrome
Hyaluronan
 addition to dialysis fluid, peritoneal ultrafiltration and, 1277-1285
 inflammatory response and peritoneal permeability during peritonitis and, 594-600
11 β -Hydroxy-steroid dehydrogenase isoforms, glucocorticoids and, 1-10
Hyperammonemia in urea cycle disorders, treatment of, 1069-1080
Hypercalcemia, doxercalciferol for secondary hyperparathyroidism in dialysis patients and, 532-543
Hypercalciuria
 in Japanese Dent's disease, 138-143
 nephrolithiasis, renal failure and, 234-235
Hypercholesterolemia, glomerular injury in, effect of soy protein alcohol-extractable components on, 832-837
Hyperglycemia, in non-insulin-dependent diabetes, renal structural changes and, 400-410
Hyperhomocysteinemia, in hemodialysis, folic vs. folic acid for, 758-765
Hyperlipidemia
 in chronic renal failure, cardioprotective drugs for, 484-489
 dietary phytoestrogens and, 1056-1068
 therapeutic plasma exchange for, effect on cyclosporine kinetics, 1286-1289
Hyperosmolar syndrome, with uncontrolled diabetes mellitus, 5:E41
Hyperoxaluria
 kidney stones in, 234-235
 renal failure and, 236-237
Hyperparathyroidism
 primary, calcium stones in, 235
 secondary
 bone mineral density and, 1247-1252

- intravenous vs. oral doxercalciferol for, 532-543
- nephrogenic ascites and, 2:E:16
- phosphorus in pathogenesis of, S2:54-57
- vitamin D derivatives for, S2:58-61
- Hyperphosphatemia**
 - doxercalciferol for secondary hyperparathyroidism in dialysis patients and, 532-543
 - and increased osteopontin in vascular smooth muscle cells, calciphylaxis and, 1267-1276
 - protein intake in long-term peritoneal dialysis and, 1313-1318
- Hyperpigmentation**, from argyria in maintenance hemodialysis, 1048-1051
- Hypertension**
 - in chronic renal failure
 - cardioprotective drugs for, 484-489
 - health maintenance organization and, 1177-1183
 - development, obesity and, 720-727
 - dyslipidemia and, 1319-1323
 - with ectopic adrenocorticotrophic hormone, hypokalemia and metabolic alkalosis, 838-846
 - essential, sporadic cases of Liddle's syndrome and, 632-635
 - functional/structural involvement of glomerular arterioles in, 1092-1097
 - glucocorticoid-associated, 1-10
 - hereditary, caused by de novo ENaC mutations, 499-504
 - in peritoneal dialysis, strict volume control for, 588-593
 - prognosis during pregnancy, renal vascular wall proteins and, 728-735
 - pseudohypertension with diffuse scleroderma, 4:E32
 - refractory, primary aldosteronism screening for, 699-705
 - renal disease progression, aldosterone mediation of, 677-686
 - residual, after adrenalectomy in primary aldosteronism, 884-889
 - salt-sensitive, nitric oxide deficiency and, 900-908
 - with unexplained hypokalemia and metabolic alkalosis, 3:E24
- Hyperuricemia**, cyclosporine-associated, allograft failure and, 871-875
- Hypoalbuminemia** in chronic dialysis patients with delayed gastric emptying, prokinetic agents for, 287-293
- Hypocalcemia**, in nonseptic critically ill patients, 689-698
- Hypocomplementemia**
 - glomerular deposits in type 2 membranoproliferative glomerulonephritis and, 1120-1130
 - and tubulointerstitial nephritis with immune deposits, 388-399
- Hypocomplementemic urticarial vasculitis syndrome**, kidney transplantation for, 144-148
- Hypokalemia**
 - with ectopic adrenocorticotrophic hormone, metabolic alkalosis and hypertension, 838-846
 - in oncogenic Cushing's syndrome with nephrotic syndrome, 4:E28
 - reversal in thyrotoxic periodic paralysis, propranolol for, 620-623
 - unexplained, with hypertension and metabolic alkalosis, 3:E24
- Hypomagnesemia**, hypocalcemia in critically ill patients and, 689-698
- Hypopharyngeal carcinoma**, with rapidly progressive glomerulonephritis, 1:E3
- Hypophosphatemia**, reversal in thyrotoxic periodic paralysis, propranolol for, 620-623
- ICU**, hypocalcemia associated with, 689-698
- Idiopathic membranous nephropathy**, prognostic indicators, 380-387
- Immune deposits**, in idiopathic hypocomplementemic interstitial nephritis, 388-399
- Immune response**, during renal transplant rejection, 518-531
- Immune thrombocytopenic purpura**, chronic childhood, membranous nephropathy associated with, 5:E40
- Immunoglobulin A glomerulonephritis**, macrophage subclasses in, 712-719
- Immunoglobulin A nephropathy**
 - progression, obesity and, 720-727
 - urinary osteopontin in, 374-379
- Immunohistochemical parameters**, idiopathic membranous nephropathy prognosis and, 380-387
- Immunologic tests**, for lupus nephritis renal flare diagnosis, 490-498
- Immunosuppression**
 - for kidney transplantation, socioeconomic variables and, 160-163
 - malacoplakia and, 1324-1329
 - viral infection reactivation and, 671-672
- Immunotactoid glomerulopathy**, with steroid-responsive massive subendothelial deposition, 3:E21
- Indoxyl sulfate renal overload**, AST-120 amelioration and renal failure progression in diabetes, S2:7-12
- Industry**, relationship with nephrologists, 210-221
- Infection-related stones**, renal failure and, 234, 238
- Influenza virus infection**, post-transplant, 659-676
- Inherited metabolic disorder**, with hyperammonemia, treatment guidelines for, 1069-1080
- Instrument development**, 11-21
- Insulin**
 - control of protein breakdown, S2:108-111
 - protein turnover in muscle and, S2:112-114
- Intensive care unit (ICU)**, hypocalcemia associated with, 689-698
- Interdialytic weight gain**, as dietary compliance measure, 247-248
- Interferon- α complications**, posterior leukoencephalopathy syndrome with hepatitis C virus infection, 4:E29
- Interleukin-1**, induction of tubular epithelial-myofibroblast transdifferentiation, 820-831
- Interleukin-6**, production in monocytes, during hemodialysis, 954-963
- Interleukin-10**, production in monocytes, during hemodialysis, 954-963
- Interleukin-6 secretion**, in bone-turnover disease vs. cultured osteoblastic cells from dialysis patients, 30-37
- International Index of Erectile Function**, sildenafil for erectile dysfunction in dialysis patients, 134-137
- Interstitial cellular infiltration**, idiopathic membranous nephropathy prognosis and, 380-387

- Interstitial fibrosis, idiopathic membranous nephropathy prognosis and, 380-387
- Interstitial nephritis, drug-induced in renal allograft, 1:E4
- Interstitial vasculitis, drug-induced in renal allograft, 1:E4
- Intimal hyperplasia, in hemodialysis access failure, 970-980
- Intracranial pressure, continuous renal replacement therapy and, 457-466
- Intradialytic hypotension, high dialysate calcium with midodrine and/or cool dialysate for, 294-299
- Intrauterine growth retardation
- in Aboriginal children, reduced renal volume and, 915-920
 - with minimal change nephrotic syndrome, 909-914
- Iron-deficiency anemia. *See* Anemia, iron-deficiency
- iron therapy
- iron dextran
 - adverse drug events, in hemodialysis, 743-749
 - for hemodialysis patients, 859-861
 - safety, vs. sodium ferric gluconate complex, 879-883
 - iron sucrose, for dialysis-associated anemia, 300-307
 - oxidative stress, melatonin prevention of, 750-757
 - in progressive renal disease, S2:30-33
 - requirements, in hemodialysis patients, antiplatelet therapy and, 80-87
 - for treating anemia of chronic kidney disease, S1:194-206, 221-222
- Isoflavones
- glomerular injury in hypercholesterolemia and, 832-837
 - role in renal disease protection, 1056-1068
- Itraconazole, with digoxin for kidney transplant recipients, 2:E18
- Japanese patients
- with Dent's disease, chloride channel 5 gene mutations in, 138-143, 227-228
 - on dialysis, CPR preference rate, 1216-1222, 1308-1309
 - polycystic kidney disease early renal death, ACE polymorphisms and, 113-118
- JC polyomavirus infection, post-transplant, 659-676
- Juvenile nephronophthisis, molecular genetic diagnosis, 1131-1139
- Ketoconazole with cyclosporine, for transplant recipients, long-term follow-up of, 510-517
- Kidney biopsy. *See* Renal biopsy
- Kidney function
- normal, in anemia of persistent nephrotic syndrome with EPO deficiency, 736-742
 - recovery after dialysis dependence following correction of total renal artery occlusion, 1:E7
 - residual. *See* Residual renal function
 - salt intake, blood pressure and, S2:34-38
 - volume reduction in Aboriginal children, 915-920
- Kidney stones. *See also* Nephrolithiasis
- in hyperoxaluria, 234-235
 - recurrence, nephrectomy for, 235
 - sterile, urinary obstruction from, 236-238
 - types of, 234-235
- Kidney transplantation
- access
 - racial aspects of, 435-437
 - reducing racial disparities in, 921-931
 - after *Streptococcus pneumoniae*-associated hemolytic uremic syndrome, 2:E15
 - allograft. *See* Allograft
 - bone mineral density in chronic hemodialysis patients and, 1247-1252
 - cyclosporine withdrawal, impact on living-related transplants, 118-124
 - donors
 - atheroembolic renal disease, immediate allograft dysfunction from, 423-426
 - cadaveric graft loss, recurrent FSGS and, 366-373
 - living, graft survival and, 366-373
 - screening for polycystic kidney disease in, 612-619
 - traits, allograft function and, 356-365
 - for hypocomplementemic urticarial vasculitis syndrome, 144-148
 - immunosuppression, socioeconomic variables and, 160-163
 - nephrologist-industry relationship and, 210-221
 - outcome
 - predialysis supplemented low-protein diet and, S2:75
 - underlying renal disease and, 1152-1161
 - process, failure to complete, 321-328
 - recipients
 - bone mineral density, quantitative heel ultrasound for, 932-937
 - with chronic nephropathy, ambulatory vs. office blood pressure measurements, 1170-1176
 - digoxin with itraconazole for, 2:E18
 - ketoconazole with cyclosporine, long-term follow-up of, 510-517
 - long-term benefits of steroid withdrawal in, 1162-1169
 - racial pairing with donor, graft loss from recurrent FSGS and, 366-373
 - sociodemographic differences, transplant rates and, 321-328
 - traits allograft function and, 356-365
 - viral infections after, 659-676
- Klebsiella pneumoniae*, polymorphonuclear granulocytes from chronic hemodialysis patients, co-amoxiclav effect on, 1253-1259
- Kt/V
- derivation from percent reduction of urea, S1:21
 - inadequate
 - error analysis for, S1:58-60
 - morbidity and cost implications of, 1223-1231
 - natural logarithm formula, S1:16, 19-20
 - prescribing errors, potential, S1:17-S18
- Lactic acidosis, thiamine deficiency in dialysis and, 427-430
- Lean body mass, hemodialysis survival and, S2:81-88
- Lectin staining, of nucleated cells in urinary sediment, 84-93
- Left ventricular hypertrophy, brain natriuretic peptide in hemodialysis patients and, 1201-1208
- Left ventricular mass index, residual hypertension after adrenalectomy for primary aldosteronism and, 884-889
- Lenarduzzi-Cacchi-Ricci kidney, calcium stones in, 235

- Leukocyte count, selective sequestration of cytokine-producing monocytes during hemodialysis, 954-963
- Leukoencephalopathy syndrome, posterior reversible in hepatitis C virus-positive long-term hemodialysis, 4:E29
 - with minimal-change nephrotic syndrome, 4:E30
- Liddle's syndrome
 - caused by de novo ENaC mutations, 499-504
 - sporadic cases of, 632-635
- Lignans, in renal disease protection, 1056-1068
- Lipid peroxidation, in monocytes of hemodialysis patients, vitamin E suppression of, 964-969
- Lipid profile, of dialysis patients, effect of lipid-lowering diet on, 1209-1215
- 5-Lipoxygenase-mediated oxidative stress, in monocytes of hemodialysis patients, vitamin E suppression of, 964-969
- Lithium intoxication, hemodialysis followed by continuous hemofiltration for, 1044-1047
- Lithogenic risk factors, for nephrolithiasis in medullary sponge kidney, 1140-1143
- Liver disease with renal failure, transjugular renal biopsy for, 1144-1151, 1304-1307
- Lupus nephritis
 - in child with AIDS, 4:E27
 - classifying, 653-657
- Macrophages
 - glomerular infiltration, in prolonged hyperglycemia, 400-410
 - interstitial, fibrosis-promoting effects of, S2:25-29
 - subclasses in PSAGN and IgAGN, 712-719
- Magnetic resonance imaging, T-2 weighted, for polycystic kidney disease screening in transplant donor, 612-619
- Malacoplakia, 6:E42
 - in immunosuppressed patient, 1324-1329
- Malnutrition
 - hypoalbuminemia, effect of prokinetic agents on, 287-293
 - protein turnover in muscle and, S2:112-114
 - survival rate of elderly hemodialysis patients and, 997-1003
- Malondialdehyde, in chronic renal failure, effect of melatonin on, 750-757
- MALT, idiopathic hypocplementemic interstitial nephritis and, 388-399
- Marginal zone B-cell lymphoma, idiopathic hypocplementemic interstitial nephritis and, 388-399
- Mass transfer area coefficient, dialysate flow rate and, 316-320
- Medical ethics
 - preference rate for CPR in Japanese dialysis patients, 1216-1222, 1308-1309
 - shared decision-making in dialysis, 1081-1091
- Medicare costs, for inadequate hemodialysis, 1223-1231
- Medication compliance, of hemodialysis patients, 246
- Medullary sponge kidney
 - calcium stones in, 235
 - nephrolithiasis, contributory metabolic factors in, 1140-1143
- Megalin
 - albumin binding, S2:18-19
 - deficiency, holoprosencephaly with low molecular weight proteinuria and, 624-628
- Melatonin, prevention of oxidative stress from anemia treatment, 750-757
- Membranoproliferative glomerulonephritis
 - posttransplantation survival and, 1152-1161
 - type 2, composition of nephritic-factor generated glomerular deposits in, 1120-1130
- Membranous nephropathy
 - associated with chronic immune thrombocytopenic purpura in childhood, 5:E40
 - HBV-associated, proteinuria in contacts of, 125-133
 - idiopathic, prognostic indicators, 380-387
 - urinary osteopontin in, 374-379
- Mesenchymal cells, interleukin-1 induced transdifferentiation, 820-831
- Mesothelial cells, PAI-1 synthesis, induction by heat-killed microorganisms, 815-819
- Metabolic alkalosis
 - bicarbonate hemodialysis for, 4:E31
 - with ectopic adrenocorticotrophic hormone, hypokalemia and hypertension, 838-846
 - extreme, bicarbonate hemodialysis for, 4:E31
 - with unexplained hypokalemia and hypertension, 3:E24
- Metabolic disorders, causing nephrolithiasis in medullary sponge kidney, 1140-1143
- Metabolic rate, glomerular filtration rate and, 164-178
- Methoprednisolone, for nephrotic syndrome, reversible posterior leukoencephalopathy development and, 4:E30
- Methylenetetrahydrofolate reductase, reduction by folicin vs. folic acid, 758-765
- Methylprednisolone pulse therapy
 - with cyclosporine and ACE inhibitor for proteinuria in familial focal segmental glomerulosclerosis, 6:E44
 - for experimental crescentic glomerulonephritis, 411-417
- Microalbuminuria
 - in diabetic renal disease, S2:5
 - progression, prevention in diabetic nephropathy, 890-899
- β_2 -Microglobulin, in Japanese Dent's disease, 138-143
- Midodrine, with high dialysate calcium and/or cool dialysate for intradialytic hypotension, 294-299
- Mineralocorticoid excess, with metabolic alkalosis, hypokalemia and hypertension, 838-846
- Minimal-change nephrotic syndrome
 - with intrauterine growth retardation, 909-914
 - with posterior reversible leukoencephalopathy, 4:E30
 - urinary osteopontin in, 374-379
- Misdiagnosis, of renal cystic disease in adults, 852-858
- Molecular genetic diagnosis, of juvenile nephronophthisis, 1131-1139
- Monocyte chemoattractant protein-1, renal disease progression and, S2:21-24
- Monocytes
 - of hemodialysis patients, 5-lipoxygenase-mediated oxidative stress, vitamin E suppression of, 964-969
 - subtype-specific sequestration during hemodialysis, 954-963
- Morbidity
 - in hemodialysis, serum ferritin as marker for, 564-572

- prediction, in peritoneal dialysis, 337-342
- Mortality
- after myocardial infarction in renal failure patients, 1191-1200
 - hemodialysis
 - dialyzer reuse and, 276-286
 - pre-ESRD erythropoietin and, 348-355
 - serum ferritin as marker for, 564-572
 - from vascular access infections at outpatient centers, 1232-1250
 - pediatric dialysis, risk factors for, 573-579
 - posttransplantation, underlying renal disease and, 1152-1161
 - for renal disease-state management, 938-944
 - renovascular disease-associated end-stage renal disease, 1184-1190
 - standardized ratio, limitations for profiling health care quality, 267-275
- Mucosa-associated lymphoid tissue, idiopathic hypocomplementemic interstitial nephritis and, 388-399
- Mupirocin prophylaxis, for staphylococcal carriers, exit-site infection reduction and, 43-48
- Muscle protein turnover, regulation of, S2:112-114
- Myopathy, uremic, in end-stage renal disease, 1098-1104
- Myosin heavy chain antibodies, in prediction of hypertension during pregnancy, 728-735
- Na-Cl cotransporter, thiazide-sensitive, blood pressure control and, S2:42-43
- Na-H exchanger isoform 3, in blood pressure control, S2:39-47
- Na-K-2Cl cotransporter, loop diuretic-sensitive, blood pressure control and, S2:43-44
- National ESRD Clinical Performance Measures Project, accountability, public policy and, 431-434
- National Kidney Foundation DOQI. *See* Dialysis Outcomes Quality Initiative
- Nephrectomy, for stone formers, 235
- Nephritic factor, glomerular deposits in type 2 membranoproliferative glomerulonephritis and, 1120-1130
- Nephritis. *See also* Glomerulonephritis
- lupus, in child with AIDS, 4:E27
 - with systemic lupus erythematosus, 653-657
 - tubulointerstitial, with immune deposits with hypocomplementemia, 388-399
- Nephrocalcinosis, renal failure and, 237
- Nephrolithiasis
- end-stage renal disease and, 235
 - expression of proteins inhibiting calcium oxalate crystallization in vitro and, 104-112
 - forms, renal failure in, 234-235
 - mechanism of renal failure in, 233, 235-241
 - medullar sponge kidney, contributory metabolic factors in, 1140-1143
- Nephrologists
- dialysis modality decisions and, 22-29
 - relationship with industry, 210-221
- Nephrology, John P. Peters and, 1113-1119
- Nephronophthisis, juvenile or type 1, molecular genetic diagnosis of, 1131-1139
- Nephropathy
- age-related, impaired angiogenesis in, 601-611
 - chronic transplant, ambulatory vs. office blood pressure measurements for, 1170-1176
 - membranous. *See* Membranous nephropathy
 - progression, dietary phytoestrogens and, 1056-1068
- Nephrosclerosis, intrauterine food restriction and, 467-476
- Nephrotic syndrome
- with hepatitis C virus infection and renal failure, 442-447
 - minimal-change. *See* Minimal-change nephrotic syndrome
 - with oncogenic Cushing's syndrome, 4:E28
- Nifedipine, vs. perindopril for normotensive type 1 diabetics with microalbuminuria, 890-899
- Nitric oxide production, effects of aging and dietary sodium intake on, 900-908
- Nitrogen balance, for long-term peritoneal dialysis, conflicting views of, 1313-1319
- Nondiabetic renal disease, proteinuria, ACE inhibitor effects on, 477-483
- Non-dialysis-dependent renal insufficiency, long-term survival after coronary angiography, 64-72
- Normalized protein catabolic rate (NPCR), calculation of, S1:15, 19
- Normouricemia, in syndrome of inappropriate antidiuretic hormone secretion, 1:E8
- Nosocomial infection, hepatitis C virus transmission during hemodialysis, 1004-1010
- NPHP1* allele, in molecular genetic diagnosis of juvenile nephronophthisis, 1131-1139
- Nursing home, continuous peritoneal dialysis in, 580-587
- Nutritional status
- assessment, for peritoneal dialysis, S1:81-83
 - in CAPD, peritoneal transport status and, 329-336
 - of CRF patients on supplemented low-protein diet, S2:71-76
 - during pregnancy, 629-631
 - short daily hemodialysis and, S2:95-98
 - survival rate of elderly hemodialysis patients and, 997-1003
- Nutrition status
- of dialysis patients, effect of lipid-lowering diet on, 1209-1215
 - hemodialysis survival and, S2:81-88
 - for long-term peritoneal dialysis, DOQI guidelines for, 1313-1319
- Obesity, primary IgA nephritis progression and, 720-727
- Obstructive nephropathy, renal failure from, 236-237
- Optic neuropathy, in uremia, 3:E23
- Oral adsorbent, amelioration of renal overload of indoxyl sulfate and renal failure progression in diabetes, S2:7-12
- Ornithine transcarbamylase deficiency, treatment guidelines for, 1069-1080
- Osmolality, urine, in partial central diabetes insipidus, 1290-1293
- Osteoblasts, from dialysis patients vs. bone turnover disease patients, 30-37
- Osteocalcin, from bone turnover disease vs. dialysis patients, 30-37

- Osteopontin
 increased expression in vascular smooth muscle cells, calciphylaxis and, 1267-1276
 urinary, in primary glomerular disease, 374-379
- Osteoporosis, in transplant recipients, assessment by quantitative heel ultrasound, 932-937
- Outpatient hemodialysis centers, vascular access infections in, 1232-1250
- Oxalate nephropathy, after star fruit ingestion, 418-422
- Oxalate toxicity, renal failure and, 236-237
- Oxidants, in progressive renal disease, S2:30-33
- Oxidative stress
 and increased growth factor expression in hemodialysis access failure, 970-980
 from iron and rHuEPO, melatonin prevention of, 750-757
 5-lipoxygenase-mediated in monocytes of hemodialysis patients, vitamin E suppression of, 964-969
- Palliative care, shared decision-making in dialysis, 1081-1091
- Pancreatic cancer, intraglomerular metastasis from, 1299-1303
- Pancreatic cysts, in differentiation of von Hippel-Lindau disease and ADPKD, 852-858
- Pancreatic islet cell tumors, in differentiation of von Hippel-Lindau disease and ADPKD, 852-858
- Parainfluenza virus infection, post-transplant, 659-676
- Parathyroid hormone (PTH). *See also* Hyperparathyroidism
 in dialysis patients vs. bone turnover disease patients, 30-37
 dysregulation in end-stage renal disease, 1310-1312
 in elderly hemodialysis patients, effect of protein intake on, 1260-1266
 hyperphosphatemia and osteopontin in calciphylaxis, 1267-1276
 plasma intact, doxercalciferol for secondary hyperparathyroidism and, 532-543
 prognostic importance in HD and PD, S2:77-80
- Parenteral-enteral nutrition, for acute renal failure, S2:89-94
- Parovirus infection, post-transplant, 659-676
- Paroxysmal nocturnal hemoglobinuria, reversible renal failure in, 2:E17
- Patient education, in selection of dialysis modality, 981-986
- Patient preferences, for cardiopulmonary resuscitation and hemodialysis discontinuation, 1216-1222
- Pauci-immune necrotizing and crescentic glomerulonephritis, early renal allograft loss in, 202-209
- PCNA, intraglomerular metastasis from pancreatic cancer and, 1299-1303
- PD. *See* Peritoneal dialysis
- Pediatric patients. *See* Children
- Percent reduction of urea (PRU), S1:21
- Pericardial effusion, in elderly uremic pericarditis patient, thoracoscopic pericardiectomy for, 1294-1298
- Pericardiectomy, thoracoscopic, for elderly uremic pericarditis patient, 1294-1298
- Perindopril, vs. nifedipine for normotensive type 1 diabetics with microalbuminuria, 890-899
- Peritoneal dialysis (PD)
 body surface area estimation, S1:78-79
 calciphylaxis, transcutaneous oxygen tension in, 797-806
 chronic, depression identification and treatment in, 1011-1017
 continuous. *See also* Continuous ambulatory peritoneal dialysis
 in extended care facility, 580-587
 dose. *See* Dose, peritoneal dialysis
 efficiency, hyaluronan addition to dialysis fluid and, 1277-1285
 ESRD CPM project 2000 report, S3:38-46
 hypertension in, strict volume control for, 588-593
 incident, Charlson Comorbidity index outcome prediction, 337-342
 initiation, rationale for, S1:109-115
 lipid profile, effect of lipid-lowering diet on, 1209-1215
 long-term nutrition, DOQI guidelines, dissenting view of, 1313-1319
 nutritional status assessment, S1:81-83
 peritonitis. *See* Peritonitis, peritoneal dialysis
 residual kidney function assessment, S1:116-118
 selection, nephrologists and, 22-29
 suitable patients for, S1:100-103
 survival, prognostic importance of nutritional markers, S2:77-80
 total body water estimation, S1:78-79
- Peritoneal dialysis, peritonitis, hyaluronan effect on inflammatory response and peritoneal permeability, 594-600
- Peritoneal transport status, nutritional status and outcome in CAPD, 329-336
- Peritonitis
 continuous ambulatory peritoneal dialysis, with uncommon organism and atypical clinical course, 1:E10
 hyaluronan effect on inflammatory response and peritoneal permeability, 594-600
 PAI-1 expression in mesothelial cells and, 815-819
 peritoneal dialysis
 once-daily cefazolin-based regimen for, 49-55
 PAI-1 expression in mesothelial cells and, 815-819
 relapsing, recombinant tissue plasminogen activator for, 149-153
 staphylococcal, in CAPD, 43-48
- Peters, John P., nephrology and, 1113-1119
- Phagocytosis
 of polymorphonuclear granulocytes from chronic hemodialysis patients, co-amoxiclav effect on, 1253-1259
 susceptibility of uremic erythrocytes, PS-recognition mechanism and, 807-814
- Pharmacokinetics, cyclosporine, effect of therapeutic plasma exchange on, 1286-1289
- Phosphatidylserine, exposure and susceptibility to erythrocyte phagocytosis in uremia, 807-814
- Phosphorus. *See also* Hyperphosphatemia
 dysregulation in end-stage renal disease, 1310-1312
 in elderly hemodialysis patients, effect of protein intake on, 1260-1266
 home daily dialysis and, S2:99-102
 intake, for long-term peritoneal dialysis, 1313-1319
 management in chronic renal failure, historical aspects of, 195-196
 in pathogenesis of secondary hyperparathyroidism, S2:54-57

- retention, management of, 197-201
- in vascular smooth muscle cells, calciphylaxis and, 1267-1276
- Phosphorus binders, for long-term peritoneal dialysis, conflicting views of, 1313-1318
- Phytoestrogens
 - dietary, role in renal disease protection, 1056-1068
 - glomerular injury in hypercholesterolemia and, 832-837
- Plasma exchange therapy, for hypocomplementemic urticarial vasculitis syndrome, 144-148
- Plasmapheresis, effect on cyclosporine kinetics, 1286-1289
- Plasminogen activator inhibitor-1
 - in CAPD, warfarin effect on, 343-347
 - expression in mesothelial cells, induction by heat-killed microorganisms, 815-819
- Platelet-derived growth factor, increased expression in hemodialysis access failure, 970-980
- Polycystic kidney disease. *See* Autosomal dominant polycystic kidney disease
- Polymorphonuclear granulocytes, from chronic hemodialysis patients, co-amoxiclav effect on, 1253-1259
- Polyomavirus infection, 1:E1
 - post-transplant, 659-676
- Polyuria, in partial central diabetes insipidus, 1290-1293
- Poststreptococcal acute glomerulonephritis, macrophage subclasses in, 712-719
- Prealbumin, serum
 - hemodialysis survival and, S2:81-88
 - prognostic importance in HD and PD, S2:77-80
- Prednisone withdrawal, long-term benefits for kidney transplant recipients, 1162-1169
- Preeclampsia
 - C4d and C4bp deposition in glomerular capillary walls, 1:E6
 - prognosis, renal vascular wall proteins and, 728-735
- Pregnancy, nutritional status during, 629-631
- Prognosis
 - indicators, in idiopathic membranous nephropathy, 380-387
 - shared decision-making in dialysis, 1081-1091
- Progressive renal disease
 - cytokines and, S2:21-24
 - dietary phytoestrogens and, 1056-1068
 - growth factors and, S2:21-24
 - iron in, S2:30-33
 - obesity and, 720-727
 - proteinuria and, S2:13-16
- Prokinetic agents, for hypoalbuminemia in chronic dialysis patients, 287-293
- Proliferating cell nuclear antigen (PCNA), intraglomerular metastasis from pancreatic cancer and, 1299-1303
- Propranolol, for thyrotoxic periodic paralysis, 620-623
- Protease inhibitors, impairment of matrix remodeling and degradation, S2:25-29
- Protein
 - breakdown, nutritional and hormonal control, S2:108-111
 - degradation, in muscle, ubiquitin-proteasome pathway and, S2:112-114
 - dietary
 - effect on phosphorus and PTH levels, 1260-1266
 - for long-term peritoneal dialysis, 1313-1319
 - overload, renal disease progression and, S2:21-24
 - reduction, for diabetic renal disease, S2:2-6
 - soy-based, in renal disease protection, 1056-1068
 - increased synthesis, anabolic factors and, S2:115-118
- Proteinase 3 antineutrophil cytoplasmic autoantibody, in *Ge-mella morbillorum*-induced shunt nephritis, 5:E38
- Protein equivalent of total nitrogen appearance, S1:81-82
- Protein inhibitors, of CaOX crystallization, in stone-forming patients, 104-112
- Proteinuria
 - cellular infiltrate response to, S2:25-29
 - in contacts with HBV-associated membranous nephropathy, 125-133
 - in diabetic nephropathy, family-based strategy for gene identification in, 638-647
 - in familial focal segmental glomerulosclerosis, pulsed methylprednisolone, cyclosporine and ACE inhibitor for, 6:E44
 - idiopathic low-molecular weight familial, chloride channel 5 gene mutations in, 138-143
 - low molecular weight, with holoprosencephaly, 624-628
 - in nondiabetic renal disease, ACE inhibitor effects on, 477-483
 - progression, dietary phytoestrogens and, 1056-1068
 - progressive renal disease and, S2:13-16
- Proximal tubule epithelial cells
 - albumin uptake in, S2:17-20
 - mediation of complement C3 biosynthesis in, 94-103
 - glucocorticoid exposure and, 1-10
- Pseudohypertension, with diffuse scleroderma, 4:E32
- PTH. *See* Parathyroid hormone
- Quality of health care, profiling, limitations of standardized mortality ratio for, 267-275
- Quality of life
 - for end-stage renal disease, development of, 11-21
 - health-related
 - in dialysis patients, 987-996
 - measurement, for ESRD patients, 11-21
 - home daily dialysis and, S2:99-102
 - impact of daily hemodialysis on, 777-789
- Quantitative computed tomography, vs. dual x-ray absorptiometry for evaluating bone mineral density in chronic hemodialysis patients, 1247-1252
- Quantitative heel ultrasound, for bone mineral density assessment in kidney transplant recipients, 932-937
- Race
 - allograft function and, 356-365
 - dialysis dosage and, S1:21
 - graft loss from recurrent FSGS and, 366-373
 - kidney transplantation access and, 435-437
- Radiation nephropathy, yttrium 90-labeled DOTATOC-associated, 847-851
- Radionuclide gastric emptying studies, of hypoalbuminemic chronic dialysis patients, prokinetic agent effects on, 287-293
- Rapid progressive glomerulonephritis, experimental, pulse methylprednisolone efficacy in, 411-417

Rats

- chronic creatine supplementation effects, 157
- crenate glomerulonephritis, pulse methylprednisolone efficacy in, 411-417
- delay of renal failure progression and fibrosis by AST-120, S2:7-12
- effect of prolonged hyperglycemia on renal structure, 400-410
- hypercholesterolemic, effect of isoflavones on glomerular injury in, 832-837
- peritoneal dialysis efficiency, hyaluronan addition to dialysis fluid and, 1277-1285
- peritonitis, hyaluronan effect on inflammatory response and peritoneal permeability, 594-600
- Receptor-mediated endocytosis, proximal tubule uptake of albumin and, S2:18
- Recombinant human erythropoietin. *See* Erythropoietin, recombinant human
- Recombinant tissue plasminogen activator, for relapsing peritonitis, 149-153
- Red blood cell transfusions, for anemia of chronic kidney disease, S1:216
- Relapse rate, in minimal change nephrotic syndrome with intrauterine growth retardation, 909-914
- Renal artery stenosis, with end-stage renal disease, incidence trends and mortality in, 1184-1190
- Renal biopsy
 - of intraglomerular metastasis from pancreatic cancer, 1299-1303
 - transjugular, for combined renal and liver disease, 1144-1151, 1304-1307
- Renal cell carcinoma, ectopic ACTH, with nephrotic syndrome, 4:E28
- Renal failure. *See* Acute renal failure; Chronic renal failure; End-stage renal disease
- Renal osteodystrophy
 - in elderly hemodialysis patients, effect of protein intake on, 1260-1266
 - osteoblastic function, factors associated with, 30-37
 - in transplant recipients, assessment by quantitative heel ultrasound, 932-937
- Renal Physicians' Association, S1:56
- Renal replacement therapy. *See also specific renal replacement therapies*
 - chronic, coronary artery disease screening for, 56-63
 - continuous, in acute brain injury, 457-466
 - indications, S1:70-71
- Renal volume reduction, in Aboriginal children, 915-920
- Renovascular disease, end-stage renal disease from, incidence trends and mortality in, 1184-1190
- Residual renal function
 - assessment of, S1:74-75, 116-118
 - contribution to clearance with thrice weekly dialysis, S1:57
 - in peritoneal dialysis with hypertension, volume control effects on, 588-593
- Respiratory virus infections, post-transplant, 668-670
- rHuEPO. *See* Erythropoietin, recombinant human
- RSV infection, post-transplant, 659-676

Salt intake

- blood pressure and, S2:34-38
- body fluid volumes and, 648-652
- restriction
 - DASH diet and, 636-637
 - with volume control for peritoneal dialysis patients with hypertension, 588-593
- Sarcoidosis, 2:E12
- Scleroderma, diffuse, with pseudohypertension, 4:E32
- Seizure, in metabolic alkalosis, bicarbonate hemodialysis for, 4:E31
- Serological tests, for renal flare diagnosis in lupus nephritis, 490-498
- Short Form Health Survey, for assessment of health-related quality of life in dialysis patients, 987-996
- Shunt nephritis, induced by *Gemella morbillorum*, proteinase 3 antineutrophil cytoplasmic autoantibody in, 5:E38
- Sickle cell, 5:E34
- Sildenafil, for erectile dysfunction in dialysis patients, 134-137
- Silver exposure, chronic, in maintenance hemodialysis patients, 1048-1051
- α -Smooth muscle actin
 - in calciphylaxis pathogenesis, 1267-1276
 - in interleukin-1 induced tubular epithelial-myofibroblast transdifferentiation, 820-831
- Smooth muscle cells, vascular, phenotypic changes, prediction of hypertension during pregnancy, 728-735
- SMR. *See* Standardized mortality ratio
- Sodium
 - dietary intake
 - of hemodialysis patients, interdialytic weight gain and, 247-262
 - total nitric oxide production and, 900-908
 - renal transport, glucocorticoid-associated hypertension and, 1-10
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SD-PAGE), of proteinuria in contacts with HBV-associated membranous nephropathy, 125-133
- Sodium ferric gluconate complex, for dialysis-associated iron deficiency anemia, 879-883
- Sodium-glucose cotransporter type-2, in renal glycosuria with selective aminoaciduria, 1039-1043
- Sodium ion channel mutations, causing Liddle's syndrome, 499-504
- Solute removal index (SUI), S1:21
- Soy protein
 - glomerular injury in hypercholesterolemia and, 832-837
 - in renal disease protection, 1056-1068
- Spinal cord injury, nephrolithiasis, renal failure and, 234
- Staghorn stones, renal insufficiency and, 234
- Standardized hospitalization ratio, for renal disease-state management, 938-944
- Standardized mortality ratio (SMR)
 - limitations for profiling health care quality, 267-275
 - for renal disease-state management, 938-944
- Staphylococcal carriers, mupirocin prophylaxis, exit-site infection reduction and, 43-48
- Staphylococcus aureus*, heat-killed, induction of PAI-1 in mesothelial cells, 815-819

- Staphylococcus epidermidis*, heat-killed, induction of PAI-1 in mesothelial cells, 815-819
- Star fruit ingestion, oxalate nephropathy after, 418-422
- Stenosis
 of hemodialysis synthetic graft, prediction, blood flow measurements for, 790-796
 recurrence, prediction after radiologic intervention in hemodialysis patients, 945-953
- Steroid dependence, in minimal change nephrotic syndrome with intrauterine growth retardation, 909-914
- Steroid-responsive massive subendothelial deposition, in immunotactoid glomerulopathy, 3:E21
- Steroid therapy, for ESRD in hypocomplementemic urticarial vasculitis syndrome, 144-148
- Steroid withdrawal, long-term benefits for kidney transplant recipients, 1162-1169
- Streptococcus pneumoniae*-associated hemolytic uremic syndrome, renal transplantation after, 2:E15
- Subacute necrotizing-encephalomyelopathy, with glomerulocystic kidney, 2:E14
- Subendothelial deposition, steroid-responsive massive, in immunotactoid glomerulopathy, 3:E21
- Survival
 of elderly hemodialysis patients, factors influencing, 997-1003
 posttransplantation, underlying renal disease and, 1152-1161
 of renal failure patients after myocardial infarction, 1191-1200
- Syndrome of apparent mineralocorticoid excess, glucocorticoid-associated hypertension and, 1-10
- Syndrome of inappropriate antidiuretic hormone secretion, normouricemia in, 1:E8
- Systemic lupus erythematosus
 hypocomplementemic urticarial vasculitis syndrome and, 146-147
 with nephritic syndrome, 653-657
 renal flare diagnosis, anti-C1q antibodies for, 490-498
- Thallium dipyrindamole scintigraphy, for CAD screening of renal replacement therapy patients, 56-63
- T helper subtype 1 immune response, during renal transplant rejection, 518-531
- Therapeutic plasma exchange, effect on cyclosporine kinetics, 1286-1289
- Thiamine deficiency, induction of chorea in hemodialysis, 427-430
- Thirst, in partial central diabetes insipidus, 1290-1293
- Thorascoscopic pericardiectomy, for elderly uremic pericarditis patient, 1294-1298
- Thrombectomy, for hemodialysis patients, prediction of arteriovenous graft patency after, 945-953
- Thrombogenesis in CAPD, warfarin effect on, 343-347
- Thrombosis
 arteriovenous graft, assessment of access blood flow after preemptive angioplasty, 1029-1038
 prediction, graft blood flow measurements for, 790-796
 recurrence, prediction after radiologic intervention in hemodialysis patients, 945-953
- Thrombospondin-1, angiogenesis impairment in aging kidney and, 601-611
- Thrombotic microangiopathy (TMA)
 caused by yttrium 90-DOTATOC internal radiotherapy, 847-851
 early allograft failure in crescentic glomerulonephritis, 202-209
- Thyroid hormones, control of protein breakdown, S2:108-111
- Thyrotoxic periodic paralysis, propranolol for, 620-623
- Tissue acoustics, in quantification of renal cortical echogenicity, 706-711
- Tissue plasminogen activator (tPA)
 for relapsing peritonitis, 149-153
 synthesis, effect of heat-killed microorganisms on, 815-819
- Total body water estimation, S1:78-79
- Total cell volume, S1:39-41
- Transcutaneous oxygen tension, in calciphylaxis, 797-806
- Transdifferentiation, tubular epithelial-myofibroblast, interleukin-1 induction of, 820-831
- Transferrin, mediation of complement C3 biosynthesis in human proximal tubular epithelial cells, 94-103
- Transferrin receptor levels, for erythropoiesis assessment during hemodialysis, 550-556
- Transferrin saturation, in dialysis-associated anemia, iron sucrose therapy for, 300-307
- Transforming growth factor- β 1
 dependence, of IL-1-induced TEMT, 820-831
 increased expression in hemodialysis access failure, 970-980
- Transjugular renal biopsy
 for combined renal and liver disease, 1144-1151, 1304-1307
 for liver disease patients with renal abnormalities, 1144-1151
- Trauma, renal allograft fracture from, 4:E33
- Tubular basement membrane thickening, in prolonged hyperglycemia, 400-410
- Tubular epithelial-myofibroblast transdifferentiation, interleukin-1 induction of, 820-831
- Tubulointerstitial lesions, intrauterine food restriction and, 467-476
- Tumor emboli, intraglomerular metastasis from pancreatic cancer and, 1299-1303
- Turin overexcretion, in renal glycosuria, 1039-1043
- Ubiquitin-proteasome-dependent proteolysis, hormone control of, S2:108-111
- Ubiquitin-proteasome pathway, protein degradation in muscle and, S2:112-114
- Ultrafiltration
 modified urea reduction ratio and, 544-549
 peritoneal, hyaluronan addition to dialysis fluid and, 1277-1285
- Ultrasonography
 inadequacy for polycystic kidney disease screening in transplant donor, 612-619
 quantification of renal cortical echogenicity, 706-711
- United Network for Organ Sharing (UNOS), relationship of transplant outcome and underlying renal disease, 1152-1161

- United States Renal Data System (USRDS)
Dialysis Morbidity and Mortality Study, results of, 276–286
graft loss from recurrent FSGS, 366–373
Urate stones, renal insufficiency and, 234
Urea
intradialytic generation, modified urea reduction ratio and, 544–549
mass transfer area coefficient, dialysate flow rate and, 316–320
removal index, S1:21
volume of distribution
anthropometric determination of, S1:56–57
kinetic determination of, S1:56
Urea cycle disorders, hyperammonemia in, 1069–1080
Urea filtration rate/volume. *See* Kt/V
Urea kinetic modeling (UKM)
advantages, S1:16–S19
disadvantages, S1:19
modified urea reduction ratio for, 544–549
single-pool *versus* double-pool effects, S1:23–25
Urea reduction ratio (URR), S1:16, 20
adjustments for ultrafiltration, S1:28–29
inadequate, error analysis for, S1:58–60
modified, to correct for ultrafiltration and intradialytic urea generation, 544–549
Uremia
during continuous ambulatory peritoneal dialysis, S2:103–107
erythrocytes, phagocytosis susceptibility, PS-recognition mechanism and, 807–814
from generalized argyria, in maintenance hemodialysis patients, 1048–1051
optic neuropathy in, 3:E23
Uric acid crystals, in gouty nephropathy with allograft failure, 871–875
Urinary obstruction, from sterile stones, 236–238
Urinary sediment, nucleated cells, lectin staining of, 84–93
Urine collection, S1:80
Urolithiasis, calcium oxalate, inhibition of CaOx crystallization in vitro, 104–112
URR. *See* Urea reduction ratio

Vaccinations, before/after kidney transplantation, 672–673
Vancomycin, for peritoneal dialysis peritonitis, 49–55
Varicella-zoster virus infection, post-transplant, 659–676
Vascular access. *See also specific vascular access methods*
blood flow rate. *See* Blood flow rate, of hemodialysis access
complications
optimal approaches for, S1:163–168
prevention of infection, S1:157–159
when to intervene, S1:160–162
diagnostic testing, S1:152–154
DOQI update, 190–191, S1:138–179
ESRD CPM project 2000 report, S3:26–28
evaluation prior to placement, S1:141–149
infection
at outpatient hemodialysis centers, 1232–1250
prevention of, S1:157–159
monitoring, S1:150, 154–155
retrograde hemodialysis access flow, as predictor of access pathology, 1241–1246
quality of care standards, S1:169–173
recirculation, retrograde hemodialysis access flow, as predictor of access pathology, 1241–1246
surveillance, S1:150–152, 154–155
survival comparison of cuffed tunneled catheters, 557–563
thrombosis prediction, blood flow measurements for, 790–796
Vascular endothelial growth factor, angiogenesis impairment in aging kidney and, 601–611
Vascular patency, of hemodialysis synthetic graft, blood flow measurement predictions for, 790–796
Vascular resistance, glucocorticoid exposure and, 1–10
Vascular smooth muscle cells
increased osteopontin expression in calciphylaxis, 1267–1276
phenotypic changes, prediction of hypertension during pregnancy, 728–735
Vasopressin, in partial central diabetes insipidus, 1290–1293
Viagra, for erectile dysfunction in dialysis patients, 134–137
Viral infections, after kidney transplantation, 659–676
Visual disturbances, in reversible posterior leukoencephalopathy with minimal-change nephrotic syndrome, 4:E30
Vitamin B₆, with folic acid for hyperhomocysteinemia, 758–765
Vitamin D
deficiency, in holoprosencephaly with low molecular weight proteinuria, 624–628
derivatives, for secondary hyperparathyroidism, S2:58–61
dysregulation in end-stage renal disease, 1310–1312
intravenous *vs.* oral doxercalciferol for secondary hyperparathyroidism in dialysis patients, 532–543
Vitamin E, suppression of 5-lipoxygenase-mediated oxidative stress in monocytes in hemodialysis patients, 964–969
Von Hippel-Lindau disease, mimicking autosomal dominant polycystic kidney disease, 852–858
Von Willebrand factor, in CAPD, warfarin effect on, 343–347

Warfarin, fixed low-dose, CAPD hemostatic factors and, 343–347
Wegener's granulomatosis, diabetes insipidus and anterior pituitary insufficiency in, 1:E5
Wernicke's encephalopathy, as chronic dialysis complication, 427–430

Yttrium 90-DOTATOC internal radiotherapy, causing thrombotic microangiopathy, 847–851

